[
    {
        "English": {
            "content": [
                {
                    "content": "Patients must not ",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib, or excipients or to dimethyl sulfoxide (DMSO) or to either carboplatin or paclitaxel",
                            "id": "3",
                            "type": "text"
                        },
                        {
                            "content": "have a known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies",
                            "id": "5",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": "have Serum Albumin > ",
                                    "id": "9",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "OTHER",
                                            "id": "11",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "10",
                                    "name": "VARIABLE2",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " g/dL",
                                    "id": "12",
                                    "type": "text"
                                },
                                {
                                    "content": " or be hypersensitive to albumin",
                                    "id": "13",
                                    "type": "text"
                                }
                            ],
                            "id": "7",
                            "type": "progression"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Hypersensitivity"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients with: ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "active brain metastases or carcinomatous meningitis or epidural disease are excluded from this clinical trial",
                            "type": "text"
                        },
                        {
                            "content": "brain metastases previously treated with whole brain radiation or radiosurgery or patients with epidural disease previously treated with radiation who are asymptomatic and have remained stable for 4 weeks and do not require steroid treatment for at least 2 weeks before starting study treatment are eligible",
                            "type": "text"
                        },
                        {
                            "content": "neurosurgical resection of brain metastases or brain biopsy are eligible if completed at least 3 months before starting study treatment; patients with known brain metastases must have baseline brain imaging with contrast-enhanced CT or MRI scans to confirm eligibility",
                            "type": "text"
                        },
                        {
                            "content": "inactive central nervous system (CNS) metastasis are eligible; inactive CNS metastasis is defined as: no signs of cerebral edema after successful definitive treatment of brain metastases (surgical resection, whole brain irradiation, stereotactic radiation therapy, or a combination of these) with stable or improved radiographic appearance on magnetic resonance imaging (MRI) scan at least 1 month after completion of treatment",
                            "type": "text"
                        },
                        {
                            "content": "with clinical evidence of pulmonary leukostasis, disseminated intravascular coagulation, or CNS leukemia are ineligible",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ".",
                    "type": "text"
                }
            ]
        },
        "name": "Metastases"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must have level of: ",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": [
                                {
                                    "content": "creatinine no greater than ",
                                    "id": "5",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "1",
                                            "id": "7",
                                            "type": "text"
                                        },
                                        {
                                            "content": "1.5",
                                            "id": "8",
                                            "type": "text"
                                        },
                                        {
                                            "content": "2",
                                            "id": "9",
                                            "type": "text"
                                        },
                                        {
                                            "content": "OTHER",
                                            "id": "10",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "6",
                                    "name": "VARIABLE2",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " x IULN",
                                    "id": "11",
                                    "type": "text"
                                }
                            ],
                            "id": "4",
                            "type": "progression"
                        },
                        {
                            "content": "Serum sodium and potassium within the institutional limits of normal",
                            "id": "12",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": "Bilirubin <= ",
                                    "id": "14",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "1.5",
                                            "id": "16",
                                            "type": "text"
                                        },
                                        {
                                            "content": "2.0",
                                            "id": "17",
                                            "type": "text"
                                        },
                                        {
                                            "content": "OTHER",
                                            "id": "18",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "15",
                                    "name": "VARIABLE3",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " x IULN",
                                    "id": "19",
                                    "type": "text"
                                }
                            ],
                            "id": "13",
                            "type": "progression"
                        },
                        {
                            "content": "Thyroid stimulating hormone (TSH) within institutional limits",
                            "id": "20",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": "Adequate coagulation defined as:* Prothrombin time (PT) <= ",
                                    "id": "22",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "1.2",
                                            "id": "24",
                                            "type": "text"
                                        },
                                        {
                                            "content": "1.3",
                                            "id": "25",
                                            "type": "text"
                                        },
                                        {
                                            "content": "1.5",
                                            "id": "26",
                                            "type": "text"
                                        },
                                        {
                                            "content": "OTHER",
                                            "id": "27",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "23",
                                    "name": "VARIABLE4",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " x IULN",
                                    "id": "28",
                                    "type": "text"
                                }
                            ],
                            "id": "21",
                            "type": "progression"
                        },
                        {
                            "content": [
                                {
                                    "content": "creatinine clearance (CC) >= ",
                                    "id": "30",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "50",
                                            "id": "32",
                                            "type": "text"
                                        },
                                        {
                                            "content": "60",
                                            "id": "33",
                                            "type": "text"
                                        },
                                        {
                                            "content": "OTHER",
                                            "id": "34",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "31",
                                    "name": "VARIABLE5",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " mL/min",
                                    "id": "35",
                                    "type": "text"
                                }
                            ],
                            "id": "29",
                            "type": "progression"
                        },
                        {
                            "content": [
                                {
                                    "content": "Gomerular filtration rate (GFR) > ",
                                    "id": "37",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "25",
                                            "id": "39",
                                            "type": "text"
                                        },
                                        {
                                            "content": "30",
                                            "id": "40",
                                            "type": "text"
                                        },
                                        {
                                            "content": "60",
                                            "id": "41",
                                            "type": "text"
                                        },
                                        {
                                            "content": "OTHER",
                                            "id": "42",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "38",
                                    "name": "VARIABLE6",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " mL/min",
                                    "id": "43",
                                    "type": "text"
                                }
                            ],
                            "id": "36",
                            "type": "progression"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "45",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": " for patients age ",
                                    "id": "47",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "5",
                                            "id": "49",
                                            "type": "text"
                                        },
                                        {
                                            "content": "10",
                                            "id": "50",
                                            "type": "text"
                                        },
                                        {
                                            "content": "12",
                                            "id": "51",
                                            "type": "text"
                                        },
                                        {
                                            "content": "15",
                                            "id": "52",
                                            "type": "text"
                                        },
                                        {
                                            "content": "16",
                                            "id": "53",
                                            "type": "text"
                                        },
                                        {
                                            "content": "OTHER",
                                            "id": "54",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "48",
                                    "name": "VARIABLE7",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " years who are ",
                                    "id": "55",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "male",
                                            "id": "57",
                                            "type": "text"
                                        },
                                        {
                                            "content": "female",
                                            "id": "58",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "56",
                                    "name": "VARIABLE8",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " , serum creatinine or creatinine clearance must be ",
                                    "id": "59",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": ".4",
                                            "id": "61",
                                            "type": "text"
                                        },
                                        {
                                            "content": ".6",
                                            "id": "62",
                                            "type": "text"
                                        },
                                        {
                                            "content": ".8",
                                            "id": "63",
                                            "type": "text"
                                        },
                                        {
                                            "content": "1.0",
                                            "id": "64",
                                            "type": "text"
                                        },
                                        {
                                            "content": "1.2",
                                            "id": "65",
                                            "type": "text"
                                        },
                                        {
                                            "content": "1.4",
                                            "id": "66",
                                            "type": "text"
                                        },
                                        {
                                            "content": "1.5",
                                            "id": "67",
                                            "type": "text"
                                        },
                                        {
                                            "content": "1.7",
                                            "id": "68",
                                            "type": "text"
                                        },
                                        {
                                            "content": "OTHER",
                                            "id": "69",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "60",
                                    "name": "VARIABLE9",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " mg/dL or radioisotope glomerular filtration rate (GFR) must be >= 70ml/min/1.73 m^2.",
                                    "id": "70",
                                    "type": "text"
                                }
                            ],
                            "id": "46",
                            "type": "progression"
                        }
                    ],
                    "id": "44",
                    "name": "VARIABLE6",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Creatinine"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must: ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": [
                                {
                                    "content": "not have received any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within ",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "14",
                                            "type": "text"
                                        },
                                        {
                                            "content": "21",
                                            "type": "text"
                                        },
                                        {
                                            "content": "28",
                                            "type": "text"
                                        },
                                        {
                                            "content": "OTHER",
                                            "type": "text"
                                        }
                                    ],
                                    "type": "dropdown"
                                },
                                {
                                    "content": "",
                                    "type": "text"
                                }
                            ],
                            "type": "progression"
                        },
                        {
                            "content": "have no excess risk of bleeding",
                            "type": "text"
                        },
                        {
                            "content": "not be planning to have the following procedures: Major surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 28 days prior to enrollment, Central line placement or subcutaneous port placement is not considered major surgery; external central lines must be placed at least 3 days prior to enrollment and subcutaneous ports must be placed at least 7 days prior to enrollment, Core biopsy within 7 days prior to enrollment, Fine needle aspirate within 7 days prior to enrollment, Surgical or other wounds must be adequately healed prior to enrollment; Note: for purposes of this study, bone marrow aspirate and biopsy are not considered surgical procedures and therefore are permitted within 14 days prior to start of protocol therapy",
                            "type": "text"
                        },
                        {
                            "content": "have recovered to at least a grade <= 1 toxicity eligibility levels due to adverse events (AEs) and/or toxicity of prior chemotherapy or biologic therapy; they must not have had chemotherapy or biologic therapy within 4 weeks (6 weeks for nitrosoureas and mitomycin C, or 2 months for UCN-01), or therapy with tyrosine kinase inhibitors within 5 times the half-life of the inhibitors prior to entering the study; patients must be >= 2 weeks since any prior administration of study drug in an exploratory investigational new drug (IND)/phase 0 study; patients must be >= 1 month since completion of any prior radiation (>= 2 weeks for palliative radiation therapy); however, patients receiving bisphosphonates for any cancer or undergoing androgen deprivation therapy for prostate cancer are eligible",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ". Surgery (partial or gross total resection or biopsy) must be performed >= ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "2",
                            "type": "text"
                        },
                        {
                            "content": "6",
                            "type": "text"
                        },
                        {
                            "content": "8",
                            "type": "text"
                        },
                        {
                            "content": "OTHER",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": " weeks prior to registration; patient must have recovered adequately from the effects of surgery.",
                    "type": "text"
                }
            ]
        },
        "name": "Surgery"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients:\n",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "must not have received prior anti-PD1 directed therapy (monoclonal antibody [mAb] or small molecule)",
                            "id": "3",
                            "type": "text"
                        },
                        {
                            "content": "may have had prior systemic therapy in the adjuvant setting (e.g. interferon, BRAF, or mitogen-activated protein kinase [MEK] agents)",
                            "id": "4",
                            "type": "text"
                        },
                        {
                            "content": "may have had prior anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) in the adjuvant setting, if at least one year from last dose of treatment has passed prior to beginning treatment",
                            "id": "5",
                            "type": "text"
                        },
                        {
                            "content": "may not have had any prior programmed cell death (PD)-1/PD-ligand (PD-L)1 agent in the adjuvant setting",
                            "id": "6",
                            "type": "text"
                        },
                        {
                            "content": "may not have had any prior ipilimumab and/or anti-PD-1/PD-L1 agent in the metastatic setting",
                            "id": "7",
                            "type": "text"
                        },
                        {
                            "content": "must not have had systemic chemotherapy or immunotherapy, including, but not limited to interferon alfa-2b, high dose interleukin 2 (IL-2), pegylated interferon (PEG-IFN), anti-programmed cell death protein 1 (PD-1), anti-PD-L1, intra-tumoral, or vaccine therapies within 6 weeks prior to cycle 1, day 1",
                            "id": "8",
                            "type": "text"
                        },
                        {
                            "content": "must not have received or be planning to receive any of the prohibited therapies during protocol treatment",
                            "id": "9",
                            "type": "text"
                        },
                        {
                            "content": "prior intravesical interferon therapy is allowed",
                            "id": "10",
                            "type": "text"
                        },
                        {
                            "content": "must not have known immune impairment who may be unable to respond to anti-cytotoxic T-lymphocyte antigen 4 (CTLA 4) antibody and/or anti-PD-1 antibody",
                            "id": "11",
                            "type": "text"
                        },
                        {
                            "content": "must not have history of severe hypersensitivity reaction to any monoclonal antibody",
                            "id": "12",
                            "type": "text"
                        },
                        {
                            "content": "must not have a history of a serious allergic or anaphylactic reaction to humanized monoclonal antibodies",
                            "id": "13",
                            "type": "text"
                        },
                        {
                            "content": "must not have a history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins",
                            "id": "14",
                            "type": "text"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Antibody"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must not have:\n",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions: Cardiovascular disorders including: Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening, Concurrent uncontrolled hypertension defined as sustained BP > 140 mm Hg systolic, or > 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment",
                            "id": "3",
                            "type": "text"
                        },
                        {
                            "content": "any history of congenital long QT syndrome",
                            "id": "4",
                            "type": "text"
                        },
                        {
                            "content": "Any of the following within 6 months before the first dose of study treatment: \nUnstable angina pectoris, clinically-significant cardiac arrhythmias, Stroke (including transient ischemic attack [TIA], or other ischemic event), Myocardial infarction, Thromboembolic event requiring therapeutic anticoagulation (note: subjects with a venous filter [e.g. vena cava filter] are not eligible for this study)",
                            "id": "5",
                            "type": "text"
                        },
                        {
                            "content": "Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including: Any of the following within 28 days before the first dose of study treatment: Intra-abdominal tumor/metastases invading GI mucosa, Active peptic ulcer disease, Inflammatory bowel disease (including ulcerative colitis and Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, malabsorption syndrome",
                            "id": "6",
                            "type": "text"
                        },
                        {
                            "content": "Any of the following within 6 months before the first dose of study treatment: \nAbdominal fistula, Gastrointestinal perforation, Bowel obstruction or gastric outlet obstruction, Intra-abdominal abscess; note: complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than 6 months before the first dose of study treatment, other disorders associated with a high risk of fistula formation including percutaneous endoscopic gastrostomy (PEG) tube placement within 3 months before the first dose of study therapy",
                            "id": "7",
                            "type": "text"
                        },
                        {
                            "content": "other clinically significant disorders such as: Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment, History of organ transplant, including allogeneic bone marrow transplant, concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment",
                            "id": "8",
                            "type": "text"
                        },
                        {
                            "content": "history of major surgery as follows: Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications, minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications. \nIn addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery.",
                            "id": "9",
                            "type": "text"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Gastrointestinal"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients taking:\n",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "3",
                            "type": "text"
                        },
                        {
                            "content": "any medications or substances that have antiviral activity against KSHV or that are strong inhibitors or inducers of cytochrome P450, family 3, subfamily A (CYP3A) or cytochrome P450, family 2, subfamily C, polypeptide 19 (2C19) are ineligible",
                            "id": "4",
                            "type": "text"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "6",
                            "type": "text"
                        },
                        {
                            "content": "antiretroviral drugs delaviridine, nevirapine, cobicistat-boosted (strong CYP3A4 inhibitor), maraviroc (sensitive CYP3A4 substrate), and PIs (strong CYP3A4 inhibitor) are ineligible",
                            "id": "7",
                            "type": "text"
                        }
                    ],
                    "id": "5",
                    "name": "VARIABLE2",
                    "type": "dropdown"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "15",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": "antibiotics",
                                    "id": "18",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "clarithromycin",
                                            "id": "21",
                                            "type": "text"
                                        },
                                        {
                                            "content": "erythromycin",
                                            "id": "22",
                                            "type": "text"
                                        },
                                        {
                                            "content": "telithromycin",
                                            "id": "23",
                                            "type": "text"
                                        },
                                        {
                                            "content": "troleandomycin",
                                            "id": "24",
                                            "type": "text"
                                        },
                                        {
                                            "content": "rifampin (rifampicin)",
                                            "id": "25",
                                            "type": "text"
                                        },
                                        {
                                            "content": "rifabutin",
                                            "id": "26",
                                            "type": "text"
                                        },
                                        {
                                            "content": "rifapentine",
                                            "id": "27",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "20",
                                    "name": "VARIABLE4",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " are ineligible",
                                    "id": "28",
                                    "type": "text"
                                }
                            ],
                            "id": "17",
                            "type": "progression"
                        }
                    ],
                    "id": "14",
                    "name": "VARIABLE3",
                    "type": "dropdown"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "30",
                            "type": "text"
                        },
                        {
                            "content": "non-nucleoside reverse transcriptase inhibitors (delaviridine, nevirapine), protease inhibitors (ritonavir, indinavir, lopinavir/ritonavir, saquinavir), cobicistat-boosted antiretrovirals (e.g., elvitegravir) are ineligible",
                            "id": "31",
                            "type": "text"
                        }
                    ],
                    "id": "29",
                    "name": "VARIABLE5",
                    "type": "dropdown"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "33",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": "antifungals ",
                                    "id": "36",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "itraconzaole",
                                            "id": "38",
                                            "type": "text"
                                        },
                                        {
                                            "content": "ketoconazole",
                                            "id": "39",
                                            "type": "text"
                                        },
                                        {
                                            "content": "voriconazole",
                                            "id": "40",
                                            "type": "text"
                                        },
                                        {
                                            "content": "fluconazole",
                                            "id": "41",
                                            "type": "text"
                                        },
                                        {
                                            "content": "posaconazole",
                                            "id": "42",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "37",
                                    "name": "VARIABLE7",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " are ineligible",
                                    "id": "43",
                                    "type": "text"
                                }
                            ],
                            "id": "35",
                            "type": "progression"
                        }
                    ],
                    "id": "32",
                    "name": "VARIABLE6",
                    "type": "dropdown"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "45",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": "antidepressants: ",
                                    "id": "48",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "nefazodone",
                                            "id": "50",
                                            "type": "text"
                                        },
                                        {
                                            "content": "antidiuretic: conivaptan",
                                            "id": "51",
                                            "type": "text"
                                        },
                                        {
                                            "content": "GI: cimetidine, aprepitant",
                                            "id": "52",
                                            "type": "text"
                                        },
                                        {
                                            "content": "hepatitis C: boceprevir, telaprevir, seville oranges, grapefruit, or grapefruit juice and/or pummelos, star fruit, exotic citrus fruits, or grapefruit hybrids",
                                            "id": "53",
                                            "type": "text"
                                        },
                                        {
                                            "content": "glucocorticoids: cortisone (> 50 mg), hydrocortisone (> 40 mg), prednisone (> 10 mg), methylprednisolone (> 8 mg), dexamethasone (> 1.5 mg)",
                                            "id": "54",
                                            "type": "text"
                                        },
                                        {
                                            "content": "anticonvulsants: phenytoin, carbamazepine, primidone, and phenobarbital and other enzyme inducing anti-convulsant drugs (EIACD)",
                                            "id": "55",
                                            "type": "text"
                                        },
                                        {
                                            "content": "St. John's Wort",
                                            "id": "56",
                                            "type": "text"
                                        },
                                        {
                                            "content": "modafinil",
                                            "id": "57",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "49",
                                    "name": "VARIABLE9",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " are ineligible",
                                    "id": "58",
                                    "type": "text"
                                }
                            ],
                            "id": "47",
                            "type": "progression"
                        }
                    ],
                    "id": "44",
                    "name": "VARIABLE8",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "CYPA"
    },
    {
        "English": {
            "content": [
                {
                    "content": [
                        {
                            "content": "Patients on enzyme-inducing anti-epileptic drugs (EIAED) are not eligible for treatment on this protocol",
                            "id": "3",
                            "type": "text"
                        },
                        {
                            "content": "patients may be on non-enzyme inducing anti-epileptic drugs or not be taking any anti-epileptic drugs",
                            "id": "4",
                            "type": "text"
                        },
                        {
                            "content": "patients previously treated with EIAED may be enrolled if they have been off the EIAED for VARIABLE2 = {\u201c10\u201d} days or more prior to the first dose of AZD1775 (MK-1775)",
                            "id": "5",
                            "type": "text"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "8",
                            "type": "text"
                        },
                        {
                            "content": "; all patients must be enrolled on AALL08B1 or Project:EveryChild (APEC14B1, if open for the classification of ALL patients) prior to treatment and enrollment",
                            "id": "9",
                            "type": "text"
                        }
                    ],
                    "id": "7",
                    "name": "VARIABLE2",
                    "type": "dropdown"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "11",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": "; For patients enrolled on AALL08B1 or APEC14B1: prior to enrollment on AALL1631, the required diagnostic bone marrow sample must have been fulfilled. For patients who have not previously enrolled on AALL08B1 or APEC14B1 (if open for ALL patients) prior to enrollment on AALL1631, a baseline diagnostic sample must be available to develop an MRD probe* In addition, laboratory reports detailing evidence of BCR-ABL1 fusion must be submitted for rapid central review within ",
                                    "id": "14",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "72",
                                            "id": "16",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "15",
                                    "name": "VARIABLE4",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " hours of study enrollment",
                                    "id": "17",
                                    "type": "text"
                                }
                            ],
                            "id": "13",
                            "type": "progression"
                        }
                    ],
                    "id": "10",
                    "name": "VARIABLE3",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Enrolled"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients may have received other prior activating immunotherapies, ",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "3",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": "but must not have received them within ",
                                    "id": "6",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "6",
                                            "id": "8",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "7",
                                    "name": "VARIABLE2",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " months prior to registration, ",
                                    "id": "9",
                                    "type": "text"
                                }
                            ],
                            "id": "5",
                            "type": "progression"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                },
                {
                    "content": "and there must be no serious unresolved complication of therapy at the time of registration.",
                    "id": "10",
                    "type": "text"
                }
            ],
            "id": "0"
        },
        "name": "Brentuximab"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must: ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": [
                                {
                                    "content": "Have a qtc msec count <= ",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "450",
                                            "type": "text"
                                        },
                                        {
                                            "content": "470",
                                            "type": "text"
                                        },
                                        {
                                            "content": "480",
                                            "type": "text"
                                        }
                                    ],
                                    "type": "dropdown"
                                },
                                {
                                    "content": " msec",
                                    "type": "text"
                                }
                            ],
                            "type": "progression"
                        },
                        {
                            "content": "avoid concomitant medication known or suspected to prolong QTc interval or cause Torsades De Pointes; if possible, alternative agents should be considered; patients who are receiving drugs that prolong the QTc are eligible if the drug is necessary and no alternatives are available",
                            "type": "text"
                        },
                        {
                            "content": "not show current evidence of significant cardiovascular disease (New York Heart Association class III or IV cardiac disease), symptomatic congestive heart failure, dilated/hypertrophic or restrictive cardiomyopathy, myocardial infarction (within the past 6 months), unstable angina, unstable arrhythmia or a need for anti-arrhythmic therapy, acute ischemia on electrocardiogram (ECG), marked baseline prolongation of QT/corrected QT (QTc) interval, orb long QT syndrome",
                            "type": "text"
                        },
                        {
                            "content": "not have a diagnosis of narcolepsy or sick sinus syndrome",
                            "type": "text"
                        },
                        {
                            "content": "not have a Known cardiac disorder, including: Uncontrolled hypertension (blood pressure [BP] of >= 150/95 despite medical support/management), Acute coronary syndrome within 6 months prior to starting treatment, prior or current cardiomyopathy including but not limited to the following: Known hypertrophic cardiomyopathy, known arrhythmogenic right ventricular cardiomyopathy, baseline left ventricular ejection fraction (LVEF) <= 55%, Previous moderate or severe impairment of left ventricular systolic function (LVEF < 50% on echocardiography or equivalent on Multi-Gated Acquisition Scan [MUGA]) even if full recovery has occurred, or severe valvular heart disease, atrial fibrillation with a ventricular rate > 100 beats per minute (bpm) on electrocardiogram (ECG) at rest",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ".",
                    "type": "text"
                }
            ]
        },
        "name": "QTC"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients:\nmust not have been treated by ",
                    "id": "2",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "PARP inhibitor",
                            "id": "4",
                            "type": "text"
                        },
                        {
                            "content": "topotecan",
                            "id": "5",
                            "type": "text"
                        },
                        {
                            "content": "monoamine oxidase inhibitor",
                            "id": "6",
                            "type": "text"
                        },
                        {
                            "content": "ABT888",
                            "id": "7",
                            "type": "text"
                        },
                        {
                            "content": "SCH727965",
                            "id": "8",
                            "type": "text"
                        },
                        {
                            "content": "CYP3A4",
                            "id": "9",
                            "type": "text"
                        },
                        {
                            "content": "vemurafenib or dabrafenib",
                            "id": "10",
                            "type": "text"
                        },
                        {
                            "content": "exemestane",
                            "id": "11",
                            "type": "text"
                        },
                        {
                            "content": "selumetenib",
                            "id": "12",
                            "type": "text"
                        },
                        {
                            "content": "dasatinib",
                            "id": "13",
                            "type": "text"
                        }
                    ],
                    "id": "3",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "15",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": ", may have been treated with ",
                                    "id": "18",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "sorafenib",
                                            "id": "20",
                                            "type": "text"
                                        },
                                        {
                                            "content": "approved tyrosine kinase inhibitor",
                                            "id": "21",
                                            "type": "text"
                                        },
                                        {
                                            "content": "imatinib",
                                            "id": "22",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "19",
                                    "name": "VARIABLE3",
                                    "type": "dropdown"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "",
                                            "id": "24",
                                            "type": "text"
                                        },
                                        {
                                            "content": [
                                                {
                                                    "content": " who have metastatic breast cancer and BRCA mutations must have received specific PARP inhibitor therapy; ",
                                                    "id": "28",
                                                    "type": "text"
                                                },
                                                {
                                                    "content": [
                                                        {
                                                            "content": "",
                                                            "id": "30",
                                                            "type": "text"
                                                        },
                                                        {
                                                            "content": "if these patients have other mutations of interest as defined in the protocol, they will be eligible to receive agents based on that mutation, and\nmust not require daily or chronic use of a proton pump inhibitor (PPI) and/or have taken a PPI within 7 days before receiving the first dose of study drug.",
                                                            "id": "31",
                                                            "type": "text"
                                                        }
                                                    ],
                                                    "id": "29",
                                                    "name": "VARIABLE5",
                                                    "type": "dropdown"
                                                }
                                            ],
                                            "id": "27",
                                            "type": "progression"
                                        }
                                    ],
                                    "id": "23",
                                    "name": "VARIABLE4",
                                    "type": "dropdown"
                                }
                            ],
                            "id": "17",
                            "type": "progression"
                        }
                    ],
                    "id": "14",
                    "name": "VARIABLE2",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Inhibitor"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must have:\n",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": [
                                {
                                    "content": "no active symptomatic ischemic heart disease, myocardial infarction or congestive heart failure within the past year; if multi gated acquisition (MUGA) is obtained, the left ventricular ejection fraction (LVEF) should exceed ",
                                    "id": "5",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "40",
                                            "id": "7",
                                            "type": "text"
                                        },
                                        {
                                            "content": "45",
                                            "id": "8",
                                            "type": "text"
                                        },
                                        {
                                            "content": "47",
                                            "id": "9",
                                            "type": "text"
                                        },
                                        {
                                            "content": "50",
                                            "id": "10",
                                            "type": "text"
                                        },
                                        {
                                            "content": "55",
                                            "id": "11",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "6",
                                    "name": "VARIABLE2",
                                    "type": "dropdown"
                                },
                                {
                                    "content": "%",
                                    "id": "12",
                                    "type": "text"
                                }
                            ],
                            "id": "4",
                            "type": "progression"
                        },
                        {
                            "content": [
                                {
                                    "content": "an Ejection fraction >= 47% by radionuclide angiogram (multi gated acquisition scan [MUGA]);",
                                    "id": "15",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "",
                                            "id": "17",
                                            "type": "text"
                                        },
                                        {
                                            "content": " Note: the echocardiogram (or MUGA) may be done within 28 days prior to enrollment",
                                            "id": "18",
                                            "type": "text"
                                        },
                                        {
                                            "content": "no presence of class III or IV heart failure",
                                            "id": "19",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "16",
                                    "name": "VARIABLE3",
                                    "type": "dropdown"
                                }
                            ],
                            "id": "14",
                            "type": "progression"
                        },
                        {
                            "content": "left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) or multi gated acquisition scan (MUGA)",
                            "id": "21",
                            "type": "text"
                        },
                        {
                            "content": "shortening fraction >= 27% by echocardiogram",
                            "id": "23",
                            "type": "text"
                        },
                        {
                            "content": "no ventricular arrhythmias except for benign premature ventricular contractions, and\na corrected QT (QTc) interval <= 450 ms",
                            "id": "24",
                            "type": "text"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Echocardiogram"
    },
    {
        "English": {
            "content": [
                {
                    "content": "For patients age <= ",
                    "id": "3",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "5",
                            "id": "13",
                            "type": "text"
                        },
                        {
                            "content": "10",
                            "id": "14",
                            "type": "text"
                        },
                        {
                            "content": "12",
                            "id": "15",
                            "type": "text"
                        },
                        {
                            "content": "15",
                            "id": "27",
                            "type": "text"
                        },
                        {
                            "content": "16",
                            "id": "28",
                            "type": "text"
                        }
                    ],
                    "id": "4",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                },
                {
                    "content": " who are",
                    "id": "18",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "male",
                            "id": "20",
                            "type": "text"
                        },
                        {
                            "content": "female",
                            "id": "29",
                            "type": "text"
                        }
                    ],
                    "id": "19",
                    "name": "VARIABLE2",
                    "type": "dropdown"
                },
                {
                    "content": ", serum creatinine or creatinine clearance must be ",
                    "id": "31",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": ".4",
                            "id": "33",
                            "type": "text"
                        },
                        {
                            "content": ".6",
                            "id": "34",
                            "type": "text"
                        },
                        {
                            "content": ".8",
                            "id": "35",
                            "type": "text"
                        },
                        {
                            "content": "1.0",
                            "id": "36",
                            "type": "text"
                        },
                        {
                            "content": "1.2",
                            "id": "37",
                            "type": "text"
                        },
                        {
                            "content": "1.4",
                            "id": "38",
                            "type": "text"
                        },
                        {
                            "content": "1.5",
                            "id": "39",
                            "type": "text"
                        },
                        {
                            "content": "1.7",
                            "id": "40",
                            "type": "text"
                        }
                    ],
                    "id": "32",
                    "name": "VARIABLE3",
                    "type": "dropdown"
                },
                {
                    "content": " or radioisotope glomerular filtration rate (GFR) must be >= 70ml/min/1.73 m^2.",
                    "id": "41",
                    "type": "text"
                }
            ],
            "id": "0"
        },
        "name": "Male"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Serum total bilirubin <= ",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "1",
                            "id": "3",
                            "type": "text"
                        },
                        {
                            "content": "1.5",
                            "id": "4",
                            "type": "text"
                        },
                        {
                            "content": "2",
                            "id": "5",
                            "type": "text"
                        },
                        {
                            "content": "OTHER",
                            "id": "6",
                            "type": "text"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                },
                {
                    "content": " x IULN",
                    "id": "7",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "9",
                            "type": "text"
                        },
                        {
                            "content": " (however, patients with known Gilbert disease who have serum bilirubin \nlevel <= 3 x ULN may be enrolled)",
                            "id": "10",
                            "type": "text"
                        }
                    ],
                    "id": "8",
                    "name": "VARIABLE2",
                    "type": "dropdown"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "12",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": " within ",
                                    "id": "15",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "7",
                                            "id": "17",
                                            "type": "text"
                                        },
                                        {
                                            "content": "14",
                                            "id": "18",
                                            "type": "text"
                                        },
                                        {
                                            "content": "21",
                                            "id": "19",
                                            "type": "text"
                                        },
                                        {
                                            "content": "OTHER",
                                            "id": "20",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "16",
                                    "name": "VARIABLE4",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " days of registration on study",
                                    "id": "21",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "",
                                            "id": "23",
                                            "type": "text"
                                        },
                                        {
                                            "content": ", serum creatinine <= 2 x institutional upper limit of normal (IULN), unless due to lymphoma, within 42 day prior to registration",
                                            "id": "24",
                                            "type": "text"
                                        },
                                        {
                                            "content": ", AST and ALT <= 3.0 x institutional upper limit of normal (IULN) within 14 days prior to registration",
                                            "id": "25",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "22",
                                    "name": "VARIABLE5",
                                    "type": "dropdown"
                                }
                            ],
                            "id": "14",
                            "type": "progression"
                        }
                    ],
                    "id": "11",
                    "name": "VARIABLE3",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Bilirubin"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must:\n",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "send tissue blocks or slides (archived paraffin-embedded tissue: 20 unstained slides or a tumor block from a prior resection must be available as a control for correlative studies) if available, to be eligible",
                            "id": "3",
                            "type": "text"
                        },
                        {
                            "content": "have tissue that has been collected within 3 months prior to registration",
                            "id": "4",
                            "type": "text"
                        },
                        {
                            "content": "have not received any intervening therapy for their cancer since the collection of the tumor sample",
                            "id": "5",
                            "type": "text"
                        },
                        {
                            "content": "have tumor tissue that meets the minimum requirements outlined",
                            "id": "6",
                            "type": "text"
                        },
                        {
                            "content": "have had all visible tumor resected completely within 60 days prior to registration; CIS disease is not expected to be completely excised",
                            "id": "7",
                            "type": "text"
                        },
                        {
                            "content": "have histologically confirmed tumor; e.g., ovarian stromal tumor [granulosa cell tumor, ganulosa cell-theca cell tumor, Sertoli-Leydig cell tumor (androblastoma), steroid (lipid) cell tumor, gynandroblastoma, unclassified sex cord-stromal tumor, sex cord tumor with annular tubules]",
                            "id": "8",
                            "type": "text"
                        },
                        {
                            "content": "have tumor amenable to percutaneous or excisional skin biopsy and be willing to undergo a tumor biopsy or biopsy samples collected on another study or from a procedure performed due to medical necessity may be acceptable if collected within 6 months prior to registration on MPACT and providing that the patient has not received any investigational or targeted treatment since that time",
                            "id": "9",
                            "type": "text"
                        },
                        {
                            "content": "have a bone marrow aspirate to obtain tumor cells if they have multiple myeloma other than plasmacytomas",
                            "id": "10",
                            "type": "text"
                        },
                        {
                            "content": "not be at risk because of the biopsy",
                            "id": "11",
                            "type": "text"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Biospecimen"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must not have:\n",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "Severe, active co-morbidity, defined as follows:* Unstable angina and/or congestive heart failure requiring hospitalization within 6 months prior to registration",
                            "id": "3",
                            "type": "text"
                        },
                        {
                            "content": "Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration",
                            "id": "4",
                            "type": "text"
                        },
                        {
                            "content": "Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration",
                            "id": "5",
                            "type": "text"
                        },
                        {
                            "content": "Idiopathic pulmonary fibrosis or other severe interstitial lung disease that requires oxygen therapy or is thought to require oxygen therapy within 1 year prior to registration",
                            "id": "6",
                            "type": "text"
                        },
                        {
                            "content": "Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for coagulation parameters are not required",
                            "id": "7",
                            "type": "text"
                        },
                        {
                            "content": "Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note: human immunodeficiency virus (HIV) testing is not required for entry into this protocol;\nGrade 3-4 electrolyte abnormalities (CTCAE, v. 4):\nSerum calcium (ionized or adjusted for albumin) < 7 mg/dl (1.75 mmol/L) or > 12.5 mg/dl (> 3.1 mmol/L) despite intervention to normalize levels, \nGlucose < 40 mg/dl (< 2.2 mmol/L) or > 250 mg/dl (> 14 mmol/L),\nMagnesium < 0.9 mg/dl (< 0.4 mmol/L) or > 3 mg/dl (> 1.23 mmol/L) despite intervention to normalize levels,\nPotassium < 3.0 mmol/L or > 6 mmol/L despite intervention to normalize levels or\nsodium < 130 mmol/L or > 155 mmol/L despite intervention to normalize levels.",
                            "id": "8",
                            "type": "text"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                },
                {
                    "content": "\nPatients must have:\nHemoglobin >= ",
                    "id": "9",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "8",
                            "id": "11",
                            "type": "text"
                        },
                        {
                            "content": "9",
                            "id": "12",
                            "type": "text"
                        },
                        {
                            "content": "10",
                            "id": "13",
                            "type": "text"
                        },
                        {
                            "content": "11",
                            "id": "14",
                            "type": "text"
                        },
                        {
                            "content": "OTHER",
                            "id": "15",
                            "type": "text"
                        }
                    ],
                    "id": "10",
                    "name": "VARIABLE2",
                    "type": "dropdown"
                },
                {
                    "content": " g/dL",
                    "id": "16",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "18",
                            "type": "text"
                        },
                        {
                            "content": " (note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable)",
                            "id": "19",
                            "type": "text"
                        }
                    ],
                    "id": "17",
                    "name": "VARIABLE3",
                    "type": "dropdown"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "21",
                            "type": "text"
                        },
                        {
                            "content": " and\nglycosylated hemoglobin measurement (HbA1c) < 7.0%.",
                            "id": "22",
                            "type": "text"
                        }
                    ],
                    "id": "20",
                    "name": "VARIABLE4",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Hemoglobin"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Serum phosphorus calcium, magnesium and potassium must be\n>= lower limit of normal",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "3",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": " within ",
                                    "id": "6",
                                    "type": "text"
                                },
                                {
                                    "content": [],
                                    "id": "7",
                                    "name": "VARIABLE2",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " days of registration",
                                    "id": "8",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "",
                                            "id": "11",
                                            "type": "text"
                                        },
                                        {
                                            "content": " and within Y days = ",
                                            "id": "12",
                                            "type": "text"
                                        },
                                        {
                                            "content": [],
                                            "id": "13",
                                            "name": "VARIABLE4",
                                            "type": "dropdown"
                                        },
                                        {
                                            "content": " days of the start of the treatment.",
                                            "id": "14",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "10",
                                    "name": "VARIABLE3",
                                    "type": "dropdown"
                                }
                            ],
                            "id": "5",
                            "type": "progression"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                },
                {
                    "content": "And serum total calcium (correct for serum albumin) or ionized calcium >= LLN",
                    "id": "15",
                    "type": "text"
                }
            ],
            "id": "0"
        },
        "name": "Ions"
    },
    {
        "English": {
            "content": [
                {
                    "content": "As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution\ufffds identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.",
                    "id": "1",
                    "type": "text"
                }
            ],
            "id": "0"
        },
        "name": "Board Approval"
    },
    {
        "English": {
            "content": [
                {
                    "content": [
                        {
                            "content": "Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event)",
                            "id": "2",
                            "type": "text"
                        },
                        {
                            "content": "patients must not have known or suspected autoimmune disease; subjects with type I diabetes mellitus, hypothyroidism requiring hormone replacement, or skin disorders not requiring systemic treatment are permitted to enroll",
                            "id": "3",
                            "type": "text"
                        },
                        {
                            "content": "patient must not have poorly controlled diabetes (defined as fasting glucose level > 200 mg/dL; optimally participants will have glucose < 150 mg/dL) despite attempts to improve glucose control by fasting duration and adjustment of medications, and fasting serum glucose must be <= 130 mg/dL",
                            "id": "4",
                            "type": "text"
                        }
                    ],
                    "id": "1",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Diabetes"
    },
    {
        "English": {
            "content": [
                {
                    "content": [
                        {
                            "content": "Patients with a primary colon or rectal cancer resection who are potentially eligible for S0820 may be pre-registered at Step 0; patients registered to Step 0 will appear on an institutional patient tracking report; patients registered to Step 0 are not registered to the S0820 protocol; to participate in S0820, patients must be registered to Step 1 after patient is consented and evaluation of eligibility; patients registered to S0820 at Step 0 continuing to Step 1 registration must use the same Southwest Oncology Group (SWOG) patient identification (ID) for registration to S0820 Step 1",
                            "type": "text"
                        },
                        {
                            "content": "Step 2 registration must be within 6 weeks of completing step 1 therapy",
                            "type": "text"
                        },
                        {
                            "content": "Patients must have adequate marrow function as evidenced by ANC >= 750/mcl within 28 days prior to registration",
                            "type": "text"
                        },
                        {
                            "content": "",
                            "type": "text"
                        },
                        {
                            "content": "Prostatectomy must have been performed greater than 365 days (1 year) prior to step 1 registration",
                            "type": "text"
                        },
                        {
                            "content": "Patients must have financial clearance for proton therapy treatment prior step 2 registration",
                            "type": "text"
                        },
                        {
                            "content": "Patients are eligible >= 6 weeks after therapeutic 131I-MIBG or if they have had prior surgery provided that all other eligibility criteria are met",
                            "type": "text"
                        },
                        {
                            "content": "Platelet count must be >= 50 x 10^9/L",
                            "type": "text"
                        },
                        {
                            "content": "AST and ALT must be < 2.5 x upper limits of normal (ULN)",
                            "type": "text"
                        },
                        {
                            "content": "",
                            "type": "text"
                        },
                        {
                            "content": "Patients must have completed treatment with any investigational agent >= 30 days prior to randomization for protocol therapy, if applicable",
                            "type": "text"
                        },
                        {
                            "content": "Aspartate aminotransferase (AST, SGOT) must be <= 2.5 x ULN",
                            "type": "text"
                        },
                        {
                            "content": "Alanine aminotransferase (ALT, SGPT) must be <= 2.5 x ULN",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ".",
                    "type": "text"
                }
            ]
        },
        "name": "Registration"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients:\n",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "must have a pre-operative magnetic resonance imaging (MRI) scan of the brain with and without contrast and computed tomography (CT) scans are NOT sufficient for study eligibility",
                            "id": "3",
                            "type": "text"
                        },
                        {
                            "content": "who undergo stereotactic biopsy only can submit a pre or post-operative MRI and for patients with M2 and M3 disease, a post-op MRI is strongly encouraged, but not mandatory to be eligible",
                            "id": "4",
                            "type": "text"
                        },
                        {
                            "content": "must have Lumbar cerebrospinal fluid (CSF) cytology examination pre-operatively or within 31 days following surgery; the optimal time for obtaining CSF is prior to surgery or 1-3 weeks following surgery; ventricular CSF (either pre- or post-op) may be used only if a post-operative spinal tap is contraindicated; if a spinal tap is contraindicated and there is no ventricular CSF available, then CSF cytology can be waived for patients with supratentorial tumors or if there is documentation of spinal subarachnoid metastases (M3); patients who are categorized as M1 must have either an intra-operative positive CSF (via lumbar puncture at the end of the procedure) or a positive lumbar CSF obtained > 7 days post-operatively",
                            "id": "5",
                            "type": "text"
                        },
                        {
                            "content": "with disease involvement of the contralateral hilar or supraclavicular lymph nodes are not eligible",
                            "id": "6",
                            "type": "text"
                        },
                        {
                            "content": "with pleural effusions that are visible on plain chest radiographs, whether cytologically positive or not, are not eligible unless they have a negative thoracentesis",
                            "id": "7",
                            "type": "text"
                        },
                        {
                            "content": "with complete surgical resection of disease are not eligible",
                            "id": "8",
                            "type": "text"
                        },
                        {
                            "content": "must not be currently enrolled in an ongoing (participating for 6 months or longer) medically prescribed diet or physical activity regimen",
                            "id": "9",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": "must have no other chronic disease (",
                                    "id": "14",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "recent myocardial infarction or unstable angina",
                                            "id": "16",
                                            "type": "text"
                                        },
                                        {
                                            "content": "chronic hepatitis",
                                            "id": "17",
                                            "type": "text"
                                        },
                                        {
                                            "content": "rheumatoid disease",
                                            "id": "18",
                                            "type": "text"
                                        },
                                        {
                                            "content": "renal or hepatic disease/dysfunction",
                                            "id": "19",
                                            "type": "text"
                                        },
                                        {
                                            "content": "diabetics receiving insulin",
                                            "id": "20",
                                            "type": "text"
                                        },
                                        {
                                            "content": "recent leg fracture",
                                            "id": "21",
                                            "type": "text"
                                        },
                                        {
                                            "content": "significant osteoarthritis",
                                            "id": "22",
                                            "type": "text"
                                        },
                                        {
                                            "content": "related orthopedic conditions",
                                            "id": "23",
                                            "type": "text"
                                        },
                                        {
                                            "content": "degenerative neurological conditions",
                                            "id": "24",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "15",
                                    "name": "VARIABLE2",
                                    "type": "dropdown"
                                },
                                {
                                    "content": ") that would preclude randomization into a lifestyle intervention trial",
                                    "id": "25",
                                    "type": "text"
                                }
                            ],
                            "id": "13",
                            "type": "progression"
                        },
                        {
                            "content": "must not have a serious psychiatric illness",
                            "id": "26",
                            "type": "text"
                        },
                        {
                            "content": "must complete all pre-entry assessments",
                            "id": "30",
                            "type": "text"
                        },
                        {
                            "content": "must have an estimated survival greater or equal to 3 months",
                            "id": "31",
                            "type": "text"
                        },
                        {
                            "content": "must have tumors determined to be easily accessible for biopsy",
                            "id": "32",
                            "type": "text"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "History"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients:\n",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "with human immunodeficiency virus (HIV) are not eligible if on anti-retroviral medications",
                            "id": "3",
                            "type": "text"
                        },
                        {
                            "content": "must be screened for HBV and HCV up to 28 days prior to study drug start using the routine hepatitis virus laboratorial panel",
                            "id": "4",
                            "type": "text"
                        },
                        {
                            "content": "must not have human T-cell leukemia virus (HTLV) type 1 and 2 (mandatory in United States [US] but optional in Canada and Europe)",
                            "id": "5",
                            "type": "text"
                        },
                        {
                            "content": "must not have an active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed)",
                            "id": "6",
                            "type": "text"
                        },
                        {
                            "content": "must have no evidence of liver damage owing to prior HCV infection, active viral, alcoholic, or other hepatitis, cirrhosis, fatty liver, or inherited liver disease",
                            "id": "7",
                            "type": "text"
                        },
                        {
                            "content": "with hepatocellular carcinoma secondary to hepatitis B or C must have test results indicative of chronic viral hepatitis infection",
                            "id": "8",
                            "type": "text"
                        },
                        {
                            "content": "with known human immunodeficiency virus (HIV) infection are eligible if they meet each of the following 3 criteria: CD4 counts >= 350 mm^3, Serum HIV viral load of < 25,000 IU/ml, and treated on a stable antiretroviral regimen",
                            "id": "9",
                            "type": "text"
                        },
                        {
                            "content": "must not have active central nervous system or meningeal involvement by lymphoma",
                            "id": "10",
                            "type": "text"
                        },
                        {
                            "content": "must not have evidence of myelodysplasia or cytogenetic abnormality indicative of \u201cmyelodysplasia on any bone marrow biopsy prior to initiation of therapy",
                            "id": "11",
                            "type": "text"
                        },
                        {
                            "content": "must not have a known bleeding diathesis, a history of stroke or intracranial hemorrhage <= 6 months before treatment, or a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or other agents used in the study",
                            "id": "12",
                            "type": "text"
                        },
                        {
                            "content": "must not have severe, active co-morbidity defined as follows: unstable angina and/or congestive heart failure requiring hospitalization within 6 months prior to registration, transmural myocardial infarction within 6 months prior to registration, acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration, chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration, idiopathic pulmonary fibrosis or other severe interstitial lung disease that requires oxygen therapy within 1 year prior to registration, history of (non-infectious) pneumonitis that required steroids or current pneumonitis, a diagnosis of immunodeficiency or systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of the MK-3475 (pembrolizumab), a known history of active TB (Bacillus tuberculosis), active autoimmune disease that has required systemic treatment in the past 2 years.",
                            "id": "13",
                            "type": "text"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Hepatitis"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients ",
                    "id": "3",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "must not be lactating females who plan to breastfeed",
                            "id": "5",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": "can be lactating females if they have agreed not to breastfeed a child while on this study and for a period of ",
                                    "id": "7",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "1",
                                            "id": "9",
                                            "type": "text"
                                        },
                                        {
                                            "content": "4",
                                            "id": "10",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "8",
                                    "name": "VARIABLE2",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " months following completion of treatment",
                                    "id": "11",
                                    "type": "text"
                                }
                            ],
                            "id": "6",
                            "type": "progression"
                        },
                        {
                            "content": "of childbearing potential are not eligible unless a negative pregnancy test result has been obtained; sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of protocol therapy",
                            "id": "12",
                            "type": "text"
                        },
                        {
                            "content": "who are men must agree to use adequate contraception prior to study entry and for the duration of study participation",
                            "id": "13",
                            "type": "text"
                        },
                        {
                            "content": "who become pregnant or suspect they are pregnant while participating in this study must inform her treating physician immediately",
                            "id": "14",
                            "type": "text"
                        }
                    ],
                    "id": "4",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Iactating"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Subjects must:\nhave blood pressure (BP) no greater than ",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "140",
                            "id": "8",
                            "type": "text"
                        },
                        {
                            "content": "150",
                            "id": "9",
                            "type": "text"
                        },
                        {
                            "content": "160",
                            "id": "10",
                            "type": "text"
                        },
                        {
                            "content": "OTHER",
                            "id": "11",
                            "type": "text"
                        }
                    ],
                    "id": "6",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                },
                {
                    "content": " mmHg systolic and ",
                    "id": "12",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "90",
                            "id": "14",
                            "type": "text"
                        },
                        {
                            "content": "100",
                            "id": "15",
                            "type": "text"
                        },
                        {
                            "content": "OTHER",
                            "id": "16",
                            "type": "text"
                        }
                    ],
                    "id": "13",
                    "name": "VARIABLE2",
                    "type": "dropdown"
                },
                {
                    "content": " mmHg diastolic for eligibility;",
                    "id": "17",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "19",
                            "type": "text"
                        },
                        {
                            "content": "initiation or adjustment of BP medication is permitted prior to study entry provided that the average of three BP readings at the time of enrollment is <= 140/90 mmHg,",
                            "id": "20",
                            "type": "text"
                        }
                    ],
                    "id": "18",
                    "name": "VARIABLE3",
                    "type": "dropdown"
                },
                {
                    "content": " not fail to achieve adequate blood pressure in spite of antihypertensive therapy for control of blood pressure,\nnot have inability to home monitor blood pressure,\nNot have a significant active cardiovascular or pulmonary disease at the time of study entry, including: Uncontrolled high blood pressure, Pulmonary hypertension, Uncontrolled asthma or oxygen saturation < 90% by pulse oximetry on room air, Significant valvular disease, severe regurgitation or stenosis by imaging independent of symptom control with medical intervention, or history of valve replacement, Medically significant (symptomatic) bradycardia, or history of arrhythmia requiring an implantable cardiac defibrillator,\nhistory of cerebrovascular accident (CVA) within 6 months, Myocardial infarction or unstable angina within 6 months, New York Heart Association grade II or greater congestive heart failure, serious and inadequately controlled cardiac arrhythmia, significant vascular disease (e.g. aortic aneurysm, history of aortic dissection), or clinically significant peripheral vascular disease.",
                    "id": "21",
                    "type": "text"
                }
            ],
            "id": "0"
        },
        "name": "Hypertension"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must: ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "have measurable or evaluable disease as defined by having one or more of the following, obtained within 28 days prior to randomization:* >= 1 g/dL monoclonal protein (M-protein) on serum protein electrophoresis* >= 200 mg/24 hours (hrs) of monoclonal protein on a 24 hour urine protein electrophoresis* Involved free light chain >= 10 mg/dL or >= 100 mg/L AND abnormal serum immunoglobulin kappa to lambda free light chain ratio (< 0.26 or > 1.65)* Monoclonal bone marrow plasmacytosis >= 30% (evaluable disease)* Serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), and serum free light chain (FLC) assay are required to be performed within 28 days prior to randomization; a bone marrow biopsy and/or aspirate is required within 28 days if bone marrow is being followed for response** NOTE: UPEP (on a 24-hour collection) is required, no substitute method is acceptable; urine must be followed monthly if the baseline urine M-spike is >= 200 mg/24 hr; please note that if both serum and urine M-components are present, both must be followed in order to evaluate response** NOTE: The serum free light chain test is required to be done if the patient does not have measurable disease in the serum or urine; measurable disease in the serum is defined as having a serum M-spike >= 1 g/dL; measurable disease in the urine is defined as having a urine M-spike >= 200 mg/24 hr",
                            "type": "text"
                        },
                        {
                            "content": "have greater than 2+ proteinuria on two consecutive dipsticks taken no less than 1 week apart or 24-hour urine protein of > 1 g; patients with < 2+ proteinuria are eligible following initial determination by urinalysis within 1 week prior to enrollment and do not need the urinalysis repeated",
                            "type": "text"
                        },
                        {
                            "content": "have Urine protein-creatinine ratio (UPCR) <= 1 on spot urinalysis or protein <= 500 mg/24 hour urine",
                            "type": "text"
                        },
                        {
                            "content": "have <= 30 mg/dl in urinalysis or <= 1+ on dipstick, unless quantitative protein is < 1000 mg in a 24 hour (h) urine sample",
                            "type": "text"
                        },
                        {
                            "content": "have a creatinine ratio urine protein creatinine (UPC) of <= 1 OR <= to 2+ proteinuria on two consecutive dipsticks taken no less than 1 week apart; UPC is the preferred test; patients with 2+ proteinuria on dipstick must also have a 24-hour urine collection demonstrating protein of <= 500 mg over 24 hours",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ".",
                    "type": "text"
                }
            ]
        },
        "name": "Protein"
    },
    {
        "English": {
            "content": [
                {
                    "content": "For randomization: ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "Bilirubin must be <= 1.5 mg/dL (obtained within 28 days prior to randomization)",
                            "type": "text"
                        },
                        {
                            "content": "Any adverse event related to step 1 therapy must have resolved to grade 2 or less",
                            "type": "text"
                        },
                        {
                            "content": "Hemoglobin must be >= 8 g/dL (within 28 days prior to randomization to Step II)",
                            "type": "text"
                        },
                        {
                            "content": "Platelet count must be >= 75,000 cells/mm^3 (within 28 days prior to randomization to Step II), Absolute neutrophil count must be >= 1000 cells/mm^3 (within 28 days prior to randomization to Step II)",
                            "type": "text"
                        },
                        {
                            "content": "Calculated creatinine clearance must be >= 30 mL/min (within 28 days prior to randomization to Step II), SGPT (ALT) and SGOT (AST) must be < 2.5 times the upper limit of normal (within 28 days prior to randomization to Step II)",
                            "type": "text"
                        },
                        {
                            "content": "ECOG-ACRIN performance status must be between 0-2",
                            "type": "text"
                        },
                        {
                            "content": "ANC must be >= 1500/mcL (1.5 x 0^9/L), obtained within 2 weeks prior to registration",
                            "type": "text"
                        },
                        {
                            "content": "All prior therapy must have been completed at least 21 days prior to enrollment (6 weeks for nitrosoureas or mitomycin C); no concomitant anti lymphoma therapy, including systemic corticosteroids for the purpose of treatment of lymphoma are allowed; topical steroids are allowed",
                            "type": "text"
                        },
                        {
                            "content": "There must be no history of Steven's Johnson's syndrome, TENs syndrome, or motor neuropathy",
                            "type": "text"
                        },
                        {
                            "content": "Patients must not have NYHA class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia",
                            "type": "text"
                        },
                        {
                            "content": "Patients must not have a serious medical or psychiatric illness likely to interfere with study participation",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ".",
                    "type": "text"
                }
            ]
        },
        "name": "Randomization"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients:\n",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "must not receive any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement) while on this study except for medications that are prescribed for supportive care but may potentially have an anti-cancer effect (i.e. megestrol acetate, bisphosphonates); these medications must have been started 1 month prior to enrollment on this study; in addition, men receiving treatment for prostate cancer will be maintained at castrate levels of testosterone by continuation of luteinizing-releasing hormone agonists",
                            "id": "3",
                            "type": "text"
                        },
                        {
                            "content": "must have received < 3 lines of prior therapy and have relapsed less than a year from their last platinum regimen; regimens that are used twice (for example carboplatin and paclitaxel) can be counted as one; if a regimen is changed during the course of treatment due to side effect profile or allergy, the course of therapy is counted as one regimen; (for example, if docetaxel is substituted for paclitaxel due to a reaction during the initial course of adjuvant therapy, this is considered one regimen)",
                            "id": "4",
                            "type": "text"
                        },
                        {
                            "content": "must have histologically documented metastatic solid tumors which have progressed after one line of therapy, or lymphoma which has progressed after all Food and Drug Administration (FDA)-approved therapy,\nthat have been previously treated with chemotherapy for hepatoblastoma or other hepatoblastoma-directed therapy (eg, radiation therapy, biologic agents, local therapy [embolization, radiofrequency ablation, laser]) are not eligible",
                            "id": "5",
                            "type": "text"
                        },
                        {
                            "content": "must be entered within 8 weeks after surgery performed for either 1) initial diagnosis, staging, and/or cytoreduction, or 2) (if done) management of recurrent disease in a chemonaive patient, any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration; continuation of hormone replacement therapy is permitted",
                            "id": "6",
                            "type": "text"
                        },
                        {
                            "content": "must have newly diagnosed active multiple myeloma (MM); except where otherwise indicated below that assessment is required within 14 days, all tests for establishing baseline disease status must be completed within 28 days prior to registration for patients with no prior therapy, or within 28 days prior to initiation of first Induction course for patients with prior therapy",
                            "id": "7",
                            "type": "text"
                        },
                        {
                            "content": "can continue use of sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement therapy; patients are eligible if these medications are discontinued prior to randomization",
                            "id": "8",
                            "type": "text"
                        },
                        {
                            "content": "must start therapy within 7 calendar days of registration",
                            "id": "9",
                            "type": "text"
                        },
                        {
                            "content": "who are receiving therapy beyond month one of initial therapy with no evidence of TB IRIS requiring corticosteroid therapy, or those receiving treatment for latent tuberculosis (INH or alternative) may be eligible after discussion with the protocol P.I.",
                            "id": "10",
                            "type": "text"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Chemotherapy"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients:\n",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "must not be lactating females who plan to breastfeed, can be lactating females if they have agreed not to breastfeed a child while on this study and for a period of ",
                            "id": "3",
                            "type": "text"
                        },
                        {
                            "content": [],
                            "id": "4",
                            "name": "VARIABLE2",
                            "type": "dropdown"
                        },
                        {
                            "content": " months \nfollowing completion of treatment,\nof childbearing potential are not eligible unless a negative pregnancy test result has been obtained; sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of protocol therapy,\nwho are men must agree to use adequate contraception prior to study entry and for the duration of study participation, and\nwho become pregnant or suspect they are pregnant while participating in this study must inform her treating physician immediately.",
                            "id": "5",
                            "type": "text"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Lactating"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients with: ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "gross residual disease or distant metastatic disease are eligible",
                            "type": "text"
                        },
                        {
                            "content": "newly diagnosed, biopsy confirmed, extracranial, non-metastatic Ewing sarcoma or primitive neuroectodermal tumor (PNET) of bone or soft tissue are eligible for this study",
                            "type": "text"
                        },
                        {
                            "content": "evidence of metastatic disease are ineligible; metastatic lesions are discontinuous from the primary tumor, are not regional lymph nodes and do not share a body cavity with the primary tumor",
                            "type": "text"
                        },
                        {
                            "content": "prior chemoembolization, radioembolization, radiofrequency ablation (RFA) or other local ablative therapies are permissible if >= 6 weeks from procedure with evidence of progression or new metastatic disease",
                            "type": "text"
                        },
                        {
                            "content": "chest x-ray negative for metastatic disease are eligible",
                            "type": "text"
                        },
                        {
                            "content": "a locally advanced and unresectable or metastatic gastroenteropancreatic neuroendocrine carcinoma that is either known or suspected to be of gastrointestinal (GI) origin are eligible",
                            "type": "text"
                        },
                        {
                            "content": "primary tumors arising from the lung, gynecologic organs or prostate are not eligible",
                            "type": "text"
                        },
                        {
                            "content": "histologically or cytologically confirmed invasive adenocarcinoma of the breast (human epidermal growth factor receptor 2 [HER2]-negative) that is locally advanced/metastatic and has progressed despite standard therapy are eligible",
                            "type": "text"
                        },
                        {
                            "content": "inflammatory breast cancer are ineligible",
                            "type": "text"
                        },
                        {
                            "content": "bisphosphonate therapy for symptomatic hypercalcemia are NOT allowed; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ".",
                    "type": "text"
                }
            ]
        },
        "name": "Metastatic"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must have: ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) on scans within the 6 month period immediately preceding enrollment for non-GBM tumors and by Response Assessment in Neuro-Oncology (RANO) criteria for GBM",
                            "type": "text"
                        },
                        {
                            "content": "measurable disease within 28 days prior to registration, tests to assess non-measurable disease must be performed within 42 days prior to registration",
                            "type": "text"
                        },
                        {
                            "content": "newly diagnosed, stage IIA \ufffd IV disease and must be entered within eight weeks from surgery",
                            "type": "text"
                        },
                        {
                            "content": "measurable disease or non-measurable disease, (defined as one or more of the following holding true: Measurable disease: Serum M-protein >= 1.0 g/dL (>= 0.5 g/dL for IgA or IgM myeloma) and/or Urine M-protein >= 200 mg/24 hours and/or Involved serum free light chain level >= 10 mg/dL AND an abnormal serum free light chain ratio; For non-measurable disease: baseline marrow burden of myeloma of at least 30%",
                            "type": "text"
                        },
                        {
                            "content": "biopsy-proven recurrent disease of any stage and have never received cytotoxic chemotherapy",
                            "type": "text"
                        },
                        {
                            "content": "non-measurable disease but must be present in at least one non-liver site, where presence is defined as 1.5 cm or greater and visualized on PET/CT with [18F]-fluorodeoxyglucose (FDG)",
                            "type": "text"
                        },
                        {
                            "content": "evaluable disease and a cancer antigen 125 (CA125) that has doubled from the post-treatment nadir and is also greater than 2 times upper limit of normal (ULN)",
                            "type": "text"
                        },
                        {
                            "content": "evidence of progressive disease after completion of radiation; at least 24 weeks must have elapsed from completion of radiation to registration",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ".",
                    "type": "text"
                }
            ]
        },
        "name": "Recist"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must not have had: ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "prior radiation therapy to the pelvis that would result in overlap of radiation therapy fields, not have had previous irradiation to the head and neck that would result in overlap in radiation fields for the current disease",
                            "type": "text"
                        },
                        {
                            "content": "prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields except patients who have progressed following stereotactic radio-surgery for 1-3 brain metastases, with at least one new lesion",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ".",
                    "type": "text"
                }
            ]
        },
        "name": "Overlap"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients:\n",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "who receive adjuvant chemotherapy after surgery may have been administered a maximum of 12 weeks of intended chemotherapy but it must be completed before randomization (if treatment delays occur, chemotherapy must be completed within 14 weeks) to be eligible",
                            "id": "3",
                            "type": "text"
                        },
                        {
                            "content": "who have had surgery for breast cancer (including re-excision of margins) must have the interval between the last and randomization be no more than 70 days to be eligible; also, if adjuvant chemotherapy was administered, the interval between the last chemotherapy treatment and randomization must be no more than 70 days to be eligible",
                            "id": "4",
                            "type": "text"
                        },
                        {
                            "content": "must have completed all chemotherapy prior to surgery; sandwich chemotherapy is not allowed (i.e. chemotherapy planned to be given after surgery)",
                            "id": "5",
                            "type": "text"
                        },
                        {
                            "content": "must have completed at least 4 cycles of neoadjuvant chemotherapy consisting of an anthracycline and/or taxane-based regimen without evidence of disease progression in the breast or the lymph nodes to be eligible",
                            "id": "6",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": "with prior invasive malignancy (except non-melanomatous skin cancer) are ineligible unless disease free for a minimum of ",
                                    "id": "9",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "2",
                                            "id": "11",
                                            "type": "text"
                                        },
                                        {
                                            "content": "3",
                                            "id": "12",
                                            "type": "text"
                                        },
                                        {
                                            "content": "5",
                                            "id": "13",
                                            "type": "text"
                                        },
                                        {
                                            "content": "OTHER",
                                            "id": "14",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "10",
                                    "name": "VARIABLE2",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " years to be eligible",
                                    "id": "15",
                                    "type": "text"
                                }
                            ],
                            "id": "8",
                            "type": "progression"
                        },
                        {
                            "content": "with noninvasive cancers (for example, carcinoma in situ of the breast, oral cavity, or cervix) are permitted even if diagnosed and treated < 3 years ago",
                            "id": "16",
                            "type": "text"
                        },
                        {
                            "content": "must have life expectancy of at least 5 years, excluding diagnosis of breast cancer (comorbid conditions should be taken into consideration, but breast cancer diagnosis is not a consideration)",
                            "id": "17",
                            "type": "text"
                        },
                        {
                            "content": "must not have other current malignancies, other than basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast; patients with other malignancies are eligible if they have been continuously disease-free for > 3 years prior to the time of registration; patients with history of RAS mutation-positive tumors are not eligible regardless of interval from the current study",
                            "id": "18",
                            "type": "text"
                        },
                        {
                            "content": "with simultaneous primaries or bilateral tumors are excluded, with the exception of patients with bilateral tonsil cancers or patients with primary tumor (T)1-2, nearby lymph nodes (N)0, metastasis (M)0 resected differentiated thyroid carcinoma, who are eligible",
                            "id": "19",
                            "type": "text"
                        },
                        {
                            "content": "must have had either breast-conserving surgery with planned radiation therapy or total mastectomy (with or without planned postmastectomy radiation) to be eligible",
                            "id": "20",
                            "type": "text"
                        },
                        {
                            "content": "must have pathologically confirmed stage IV or unresectable stage III melanoma; patients must not have disease that is suitable for local therapy, administered with curative intent to be eligible",
                            "id": "21",
                            "type": "text"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Cancer"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must: ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": [
                                {
                                    "content": "have Zubrod performance status ",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "0",
                                            "type": "text"
                                        },
                                        {
                                            "content": "1",
                                            "type": "text"
                                        },
                                        {
                                            "content": "2",
                                            "type": "text"
                                        },
                                        {
                                            "content": "OTHER",
                                            "type": "text"
                                        }
                                    ],
                                    "type": "dropdown"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "",
                                            "type": "text"
                                        },
                                        {
                                            "content": "prior to consolidation chemotherapy",
                                            "type": "text"
                                        }
                                    ],
                                    "type": "dropdown"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "",
                                            "type": "text"
                                        },
                                        {
                                            "content": [
                                                {
                                                    "content": "and within ",
                                                    "type": "text"
                                                },
                                                {
                                                    "content": [
                                                        {
                                                            "content": "14",
                                                            "type": "text"
                                                        },
                                                        {
                                                            "content": "21",
                                                            "type": "text"
                                                        },
                                                        {
                                                            "content": "28",
                                                            "type": "text"
                                                        },
                                                        {
                                                            "content": "30",
                                                            "type": "text"
                                                        },
                                                        {
                                                            "content": "45",
                                                            "type": "text"
                                                        },
                                                        {
                                                            "content": "60",
                                                            "type": "text"
                                                        }
                                                    ],
                                                    "type": "dropdown"
                                                },
                                                {
                                                    "content": " days prior to enrollment",
                                                    "type": "text"
                                                }
                                            ],
                                            "type": "progression"
                                        }
                                    ],
                                    "type": "dropdown"
                                }
                            ],
                            "type": "progression"
                        },
                        {
                            "content": [
                                {
                                    "content": "",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "60",
                                            "type": "text"
                                        },
                                        {
                                            "content": "70",
                                            "type": "text"
                                        }
                                    ],
                                    "type": "dropdown"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "",
                                            "type": "text"
                                        },
                                        {
                                            "content": "for patients > 16 years of age to be eligible (i.e. the patient must be able to care for himself/herself with occasional help from others)",
                                            "type": "text"
                                        }
                                    ],
                                    "type": "dropdown"
                                }
                            ],
                            "type": "progression"
                        },
                        {
                            "content": [
                                {
                                    "content": "have a Lansky performance status score >= ",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "",
                                            "type": "text"
                                        },
                                        {
                                            "content": "60",
                                            "type": "text"
                                        },
                                        {
                                            "content": "70",
                                            "type": "text"
                                        }
                                    ],
                                    "type": "dropdown"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "",
                                            "type": "text"
                                        },
                                        {
                                            "content": "for patients <= 16 years of age to be eligible (patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score)",
                                            "type": "text"
                                        }
                                    ],
                                    "type": "dropdown"
                                }
                            ],
                            "type": "progression"
                        },
                        {
                            "content": "have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2, or 3 within 28 days prior to registration",
                            "type": "text"
                        },
                        {
                            "content": "have been relatively stable for at least 7 days if they have neurologic deficits and CNS tumors  prior to study enrollment",
                            "type": "text"
                        },
                        {
                            "content": "have life expectancy > 8 weeks",
                            "type": "text"
                        },
                        {
                            "content": "be post-menopausal; post-menopausal will be defined as women meeting any of the following criteria: >= 60 years of age; or < 60 years of age and amenorrheic for >= 12 months prior to day 1 if uterus/ovaries are intact; or < 60 years of age, and the last menstrual period 6-12 months prior to day 1, if intact uterus/ovaries and meets biochemical criteria for menopause (follicle-stimulating hormone [FSH] and estradiol within institutional standard for postmenopausal status); or < 60 years of age, without a uterus, and meets biochemical criteria for menopause (FSH and estradiol within institutional standards for postmenopausal status); or < 60 years of age and history of bilateral oophorectomy; surgery must have been completed at least 4 weeks prior to day 1; or Prior radiation castration with amenorrhea for at least 6 months",
                            "type": "text"
                        },
                        {
                            "content": "have Hemoglobin >= 8 g/dL for patients <= 16 years of age; >= 9 g/dL for patients > 16 years of age, have body mass index (BMI) >= 3rd percentile for age, as defined by WHO criteria for patients 1-2 years of age and Centers for Disease Control and Prevention (CDC) criteria for patients > 2 years of age to be eligible",
                            "type": "text"
                        },
                        {
                            "content": "have a bone age of equal to or greater than 12 years of age as determined by local read of appropriate radiographic imaging if patient is female",
                            "type": "text"
                        },
                        {
                            "content": "have a bone age of equal to or greater than 14 years of age as determined by local read of appropriate radiographic imaging if patient is male",
                            "type": "text"
                        },
                        {
                            "content": "must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) to be considered for Cohort 1 (Stratum 1: Patients >= 11 years of age but < 18 year; Stratum 2: Patients >= 11 years of age but < 50 years)",
                            "type": "text"
                        },
                        {
                            "content": "be > than 12 months and <= 21 years of age at the time of study enrollment for Phase 1 (Part A)",
                            "type": "text"
                        },
                        {
                            "content": "be > than 12 months and <= 30 years of age at the time of study enrollment for Phase 2 (Part B and Part C)",
                            "type": "text"
                        },
                        {
                            "content": "be <= 40 years of age at the time of enrollment for Efficacy Phase",
                            "type": "text"
                        },
                        {
                            "content": "have had a cancer diagnosis < 22 years of age, irrespective of current age to be enrolled",
                            "type": "text"
                        },
                        {
                            "content": "have completed cancer treatment >= 2 years prior to study enrollment",
                            "type": "text"
                        },
                        {
                            "content": "be > 36 weeks gestational age if infant at the time of enrollment",
                            "type": "text"
                        },
                        {
                            "content": "be < 11 years of age at enrollment for Standard risk 1",
                            "type": "text"
                        },
                        {
                            "content": "be >= 11 and < 25 years of age at enrollment for Standard risk 2",
                            "type": "text"
                        },
                        {
                            "content": "be >= 11 and < 25 years old at enrollment",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ".",
                    "type": "text"
                }
            ]
        },
        "name": "Performance"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must have:\nA life expectancy of greater than",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                },
                {
                    "content": " weeks.",
                    "id": "3",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "5",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": "For tumor sequencing biopsy patients, life expectancy must be greater than ",
                                    "id": "8",
                                    "type": "text"
                                },
                                {
                                    "content": [],
                                    "id": "9",
                                    "name": "VARIABLE3",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " months.",
                                    "id": "10",
                                    "type": "text"
                                }
                            ],
                            "id": "7",
                            "type": "progression"
                        }
                    ],
                    "id": "4",
                    "name": "VARIABLE2",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Life Expectancy"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients:\n",
                    "id": "27",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "must have signed an approved informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization",
                            "id": "3",
                            "type": "text"
                        },
                        {
                            "content": "must be able and willing to give informed consent/assent",
                            "id": "4",
                            "type": "text"
                        },
                        {
                            "content": "must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines",
                            "id": "5",
                            "type": "text"
                        },
                        {
                            "content": "or their legal guardians (if the patient is < 18 years old) or durable power of attorney (DPA) must sign a document of informed consent indicating their understanding of the investigational nature and the risks of this study; when appropriate, pediatric patients will be included in all discussions in order to obtain verbal assent",
                            "id": "6",
                            "type": "text"
                        },
                        {
                            "content": "who initially consent to be on study but withdraw consent for PK study will be taken off study and replaced",
                            "id": "7",
                            "type": "text"
                        },
                        {
                            "content": "must be made aware of their other treatment options",
                            "id": "8",
                            "type": "text"
                        },
                        {
                            "content": "must be made aware that participation is voluntary",
                            "id": "9",
                            "type": "text"
                        },
                        {
                            "content": "must provide study-specific informed consent prior to study entry, including consent for mandatory tumor tissue, serum, and blood submission for immune correlatives (all patients) and p16 analysis (oropharyngeal cases only)",
                            "id": "10",
                            "type": "text"
                        },
                        {
                            "content": "must not have a medical or psychiatric illness, active substance abuse, or social circumstances that precludes ability to give informed consent or is likely to interfere with the ability to comply with the protocol stipulations",
                            "id": "11",
                            "type": "text"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Consent"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients: ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": [
                                {
                                    "content": "with serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) or serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) <= ",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "",
                                            "type": "text"
                                        }
                                    ],
                                    "type": "dropdown"
                                },
                                {
                                    "content": "in the absence of hepatic metastasis are eligible (for the purpose of this study, the ULN for SGPT is 45 U/L)",
                                    "type": "text"
                                }
                            ],
                            "type": "progression"
                        },
                        {
                            "content": "with SGPT (ALT) <= 3 x ULN or SGOT (AST) <= 5 x ULN in the presence of hepatic metastasis",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": " are eligible.",
                    "type": "text"
                }
            ]
        },
        "name": "Transaminase"
    },
    {
        "English": {
            "content": [
                {
                    "content": [
                        {
                            "content": "Patients on enzyme-inducing anti-epileptic drugs (EIAED) \nare not eligible for treatment on this protocol;",
                            "id": "3",
                            "type": "text"
                        },
                        {
                            "content": "patients may be on non-enzyme inducing anti-epileptic drugs or not be taking any anti-epileptic drugs;",
                            "id": "4",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": "patients previously treated with EIAED may be enrolled if they have been off the \nEIAED for ",
                                    "id": "7",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "10",
                                            "id": "9",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "8",
                                    "name": "VARIABLE2",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " days or more prior to the first dose of AZD1775 (MK-1775).",
                                    "id": "10",
                                    "type": "text"
                                }
                            ],
                            "id": "6",
                            "type": "progression"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "12",
                            "type": "text"
                        },
                        {
                            "content": "All patients must be enrolled on AALL08B1 or Project:EveryChild (APEC14B1, if open for the classification of ALL patients) prior to treatment and enrollment.",
                            "id": "13",
                            "type": "text"
                        }
                    ],
                    "id": "11",
                    "name": "VARIABLE3",
                    "type": "dropdown"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "15",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": "For patients enrolled on AALL08B1 or APEC14B1: prior to enrollment on AALL1631, the required diagnostic bone marrow sample must have been fulfilled. For patients who have not previously enrolled on AALL08B1 or APEC14B1 (if open for ALL patients) prior to enrollment on AALL1631, a baseline diagnostic sample must be available to develop an MRD probe* In addition, laboratory reports detailing evidence of BCR-ABL1 fusion must be submitted for rapid central review within ",
                                    "id": "18",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "72",
                                            "id": "20",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "19",
                                    "name": "VARIABLE5",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " hours of study enrollment.",
                                    "id": "21",
                                    "type": "text"
                                }
                            ],
                            "id": "17",
                            "type": "progression"
                        }
                    ],
                    "id": "14",
                    "name": "VARIABLE4",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Exposure"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients: ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C, 3 weeks for rituximab) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients who have been administered ABT-888 as part of a single or limited dosing study, such as a phase 0 study are eligible",
                            "type": "text"
                        },
                        {
                            "content": "who have had treatment with glucocorticoids, hydroxyurea, and tyrosine kinase inhibitors up to 24 hour prior to initiation of therapy are eligible",
                            "type": "text"
                        },
                        {
                            "content": "who have had prior surgery must be >= 4 weeks from registration and patients must be fully recovered from post-surgical complications to be eligible",
                            "type": "text"
                        },
                        {
                            "content": "who have received prior cabozantinib or inhibitors of c-MET or HGF are ineligible",
                            "type": "text"
                        },
                        {
                            "content": "who have received prior chemotherapy, radiotherapy, or antibody therapy for lymphoma are ineligible",
                            "type": "text"
                        },
                        {
                            "content": "and who have low grade glioma are ineligible",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ".",
                    "type": "text"
                }
            ]
        },
        "name": "Mitomycin Mitomy"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients: ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "can be eligible 6 weeks after date of autologous stem cell infusion following myeloablative therapy (timed from first day of protocol therapy)",
                            "type": "text"
                        },
                        {
                            "content": "are not eligible post allogeneic stem cell transplant",
                            "type": "text"
                        },
                        {
                            "content": "must not have had prior liver transplant",
                            "type": "text"
                        },
                        {
                            "content": "must not have received any non-protocol therapy outside of the assigned induction therapy including stem cell transplant",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": "may have undergone allogeneic hematopoietic stem cell transplantation (HSCT) (regardless of stem cell source) provided the patient is ",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "",
                                            "type": "text"
                                        }
                                    ],
                                    "type": "dropdown"
                                },
                                {
                                    "content": "days away from the transplant",
                                    "type": "text"
                                }
                            ],
                            "type": "progression"
                        },
                        {
                            "content": "must have disease that has relapsed and or is refractory to prior therapy, which must have included a multiagent chemotherapy regimen and prior ibrutinib or other BTK inhibitor therapy; patients must have relapsed following or be ineligible for, or refuse, autologous stem cell transplant, and\nwho are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ".",
                    "type": "text"
                }
            ]
        },
        "name": "Transplant"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must: ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "be able to swallow and absorb the medication",
                            "type": "text"
                        },
                        {
                            "content": "not have any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous [IV] alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow, retain, and/or absorb the drug are excluded",
                            "type": "text"
                        },
                        {
                            "content": "not have any lesion, whether induced by tumor, radiation or other conditions, which makes it difficult to swallow capsules or pills, prior surgical procedures affecting absorption including, but not limited to major resection of stomach or small bowel, Active peptic ulcer disease or Malabsorption syndrome",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ".",
                    "type": "text"
                }
            ]
        },
        "name": "Swallow"
    },
    {
        "English": {
            "content": [
                {
                    "content": "For participants not on the Hodgkin lymphoma expansion cohort, Subjects must have: Leukocytes count: no lower limit",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": " units/mm^3",
                    "id": "6",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "9",
                            "type": "text"
                        },
                        {
                            "content": ", within 2 weeks prior to enrollment",
                            "id": "10",
                            "type": "text"
                        }
                    ],
                    "id": "8",
                    "name": "VARIABLE2",
                    "type": "dropdown"
                },
                {
                    "content": ", Absolute neutrophil count >= ",
                    "id": "11",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "500 units/mcL",
                            "id": "13",
                            "type": "text"
                        }
                    ],
                    "id": "12",
                    "name": "VARIABLE3",
                    "type": "dropdown"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "15",
                            "type": "text"
                        },
                        {
                            "content": " within 2 weeks prior to enrollment",
                            "id": "16",
                            "type": "text"
                        }
                    ],
                    "id": "14",
                    "name": "VARIABLE4",
                    "type": "dropdown"
                },
                {
                    "content": ", Platelets >= ",
                    "id": "17",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "OTHER",
                            "id": "19",
                            "type": "text"
                        }
                    ],
                    "id": "18",
                    "name": "VARIABLE5",
                    "type": "dropdown"
                },
                {
                    "content": " units/mm^3",
                    "id": "20",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "22",
                            "type": "text"
                        },
                        {
                            "content": " within 2 weeks prior to enrollment",
                            "id": "23",
                            "type": "text"
                        }
                    ],
                    "id": "21",
                    "name": "VARIABLE6",
                    "type": "dropdown"
                },
                {
                    "content": ", Serum lipase and amylase < ",
                    "id": "24",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "1.5",
                            "id": "26",
                            "type": "text"
                        }
                    ],
                    "id": "25",
                    "name": "VARIABLE7",
                    "type": "dropdown"
                },
                {
                    "content": " x ULN",
                    "id": "27",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "29",
                            "type": "text"
                        },
                        {
                            "content": " within 2 weeks prior to enrollment",
                            "id": "30",
                            "type": "text"
                        }
                    ],
                    "id": "28",
                    "name": "VARIABLE8",
                    "type": "dropdown"
                },
                {
                    "content": ", AST (SGOT) / ALT (SGPT): =< ",
                    "id": "124",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "3",
                            "id": "26",
                            "type": "text"
                        }
                    ],
                    "id": "125",
                    "name": "VARIABLE7",
                    "type": "dropdown"
                },
                {
                    "content": " x ULN",
                    "id": "127",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "29",
                            "type": "text"
                        },
                        {
                            "content": " within 2 weeks prior to enrollment",
                            "id": "30",
                            "type": "text"
                        }
                    ],
                    "id": "128",
                    "name": "VARIABLE8",
                    "type": "dropdown"
                },
                {
                    "content": ", Creatinine < 1.5x upper normal limit (UNL)",
                    "id": "31",
                    "type": "text"
                },
                {
                    "content": " or CrCl > ",
                    "id": "34",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "50",
                            "id": "36",
                            "type": "text"
                        }
                    ],
                    "id": "35",
                    "name": "VARIABLE10",
                    "type": "dropdown"
                },
                {
                    "content": " ml/min",
                    "id": "37",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "39",
                            "type": "text"
                        },
                        {
                            "content": " within 2 weeks prior to enrollment",
                            "id": "40",
                            "type": "text"
                        }
                    ],
                    "id": "38",
                    "name": "VARIABLE11",
                    "type": "dropdown"
                },
                {
                    "content": ", Hemoglobin >= ",
                    "id": "42",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "9",
                            "id": "44",
                            "type": "text"
                        }
                    ],
                    "id": "43",
                    "name": "VARIABLE 12",
                    "type": "dropdown"
                },
                {
                    "content": " g/dL",
                    "id": "45",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "47",
                            "type": "text"
                        },
                        {
                            "content": " unless bone marrow involvement secondary to Hodgkin lymphoma is present, within 2 weeks prior to enrollment",
                            "id": "48",
                            "type": "text"
                        },
                        {
                            "content": " within 2 weeks prior to enrollment",
                            "id": "78",
                            "type": "text"
                        },
                        {
                            "content": " unless bone marrow involvement secondary to Hodgkin lymphoma is present",
                            "id": "79",
                            "type": "text"
                        }
                    ],
                    "id": "46",
                    "name": "VARIABLE13",
                    "type": "dropdown"
                },
                {
                    "content": ", Serum albumin >= ",
                    "id": "49",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "2.8",
                            "id": "51",
                            "type": "text"
                        }
                    ],
                    "id": "50",
                    "name": "VARIABLE14",
                    "type": "dropdown"
                },
                {
                    "content": " g/dL",
                    "id": "52",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "54",
                            "type": "text"
                        },
                        {
                            "content": " within 2 weeks prior to enrollment",
                            "id": "55",
                            "type": "text"
                        }
                    ],
                    "id": "53",
                    "name": "VARIABLE15",
                    "type": "dropdown"
                },
                {
                    "content": ".",
                    "id": "76",
                    "type": "text"
                }
            ],
            "id": "0"
        },
        "name": "Hodgkin 2"
    },
    {
        "English": {
            "content": [
                {
                    "content": "At least ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "14",
                            "type": "text"
                        },
                        {
                            "content": "21",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": "\n\n\nAnd patients with solid tumors must not have received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea).\n\nAt least ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "14",
                            "type": "text"
                        },
                        {
                            "content": "21",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": " days must have elapsed since completion of myelosuppressive therapy, > 42 days must have elapsed if nitrosurea, patient must have received last dose of immunomodulatory treatment > 21 days prior to enrollment, and patients with solid tumors must not have received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea).",
                    "type": "text"
                }
            ]
        },
        "name": "Myelosuppressive"
    },
    {
        "English": {
            "content": [
                {
                    "content": "For treatment, patients must: ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "have histologically confirmed solid tumors that have progressed on standard therapy known to prolong survival or for which no standard treatment options exist",
                            "type": "text"
                        },
                        {
                            "content": "have had histologic verification of malignancy at original diagnosis or relapse except in patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of cerebrospinal fluid (CSF) or serum tumor markers including alpha-fetoprotein or beta-human chorionic gonadotropin (HCG)",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ".\nFor diagnosis, patients who: ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "have had relapsed or refractory solid tumors including central nervous system (CNS) tumors without bone marrow involvement are eligible; patients must have had histologic verification of malignancy at original diagnosis or relapse except in patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of cerebrospinal fluid (CSF) or serum tumor markers including alpha-fetoprotein or beta-human chorionic gonadotropin (HCG). Patients with relapsed or refractory Ewing sarcoma or peripheral PNET are eligible; patients must have had histologic verification of malignancy at original diagnosis or relapse. Patients must have 2nd or greater relapse of pre-B Acute lymphoblastic leukemias (ALL) or T-cell ALL; patients may not have refractory disease. Patients with ALL must have had histologic verification of the malignancy at the most recent relapse, including immunophenotyping to confirm diagnosis.",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                }
            ]
        },
        "name": "Tumors"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must:\n",
                    "id": "27",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": [
                                {
                                    "content": "have been off corticosteroids for \n>= ",
                                    "id": "4",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "5",
                                            "id": "6",
                                            "type": "text"
                                        },
                                        {
                                            "content": "7",
                                            "id": "7",
                                            "type": "text"
                                        },
                                        {
                                            "content": "OTHER",
                                            "id": "8",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "5",
                                    "name": "VARIABLE2",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " days prior to the start of chemotherapy",
                                    "id": "9",
                                    "type": "text"
                                }
                            ],
                            "id": "3",
                            "type": "progression"
                        },
                        {
                            "content": [
                                {
                                    "content": "be on a stable or decreasing dose for at least >= ",
                                    "id": "12",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "5",
                                            "id": "14",
                                            "type": "text"
                                        },
                                        {
                                            "content": "14",
                                            "id": "15",
                                            "type": "text"
                                        },
                                        {
                                            "content": "OTHER",
                                            "id": "16",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "13",
                                    "name": "VARIABLE4",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " days prior to baseline magnetic resonance imaging (MRI) or computed tomography (CT) if GBM patient is receiving corticosteroids",
                                    "id": "17",
                                    "type": "text"
                                }
                            ],
                            "id": "11",
                            "type": "progression"
                        },
                        {
                            "content": "have been taking a stable dose of corticosteroids for symptom management for at least 1 week before baseline MRI",
                            "id": "18",
                            "type": "text"
                        }
                    ],
                    "id": "1",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "20",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": " and if used to modify immune adverse events related to prior therapy, >= ",
                                    "id": "22",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "14",
                                            "id": "25",
                                            "type": "text"
                                        },
                                        {
                                            "content": "OTHER",
                                            "id": "26",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "23",
                                    "name": "VARIABLE6",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " days must have elapsed since last dose of corticosteroid.",
                                    "id": "24",
                                    "type": "text"
                                }
                            ],
                            "id": "21",
                            "type": "progression"
                        }
                    ],
                    "id": "19",
                    "name": "VARIABLE5",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Corticosteroids"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "with solid tumors without known bone marrow involvement",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": "peripheral absolute neutrophil count (ANC) must be >= ",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "750",
                                            "type": "text"
                                        },
                                        {
                                            "content": "1000",
                                            "type": "text"
                                        },
                                        {
                                            "content": "OTHER",
                                            "type": "text"
                                        }
                                    ],
                                    "type": "dropdown"
                                },
                                {
                                    "content": " units/mm^3",
                                    "type": "text"
                                }
                            ],
                            "type": "progression"
                        },
                        {
                            "content": "Platelet count must be >= 50,000/uLm",
                            "type": "text"
                        },
                        {
                            "content": "hemoglobin must be>= 8.0 g/dL",
                            "type": "text"
                        },
                        {
                            "content": "who have received a prior solid organ transplantation are not eligible",
                            "type": "text"
                        },
                        {
                            "content": "must have diagnostic bone marrow and peripheral blood specimens submitted for immunophenotyping and selected molecular testing",
                            "type": "text"
                        },
                        {
                            "content": "must have a unilateral or bilateral bone marrow biopsy performed within 42 days prior to registration",
                            "type": "text"
                        },
                        {
                            "content": "must show no evidence of bone metastases (M0) on bone scan within 120 days prior to registration (sodium fluoride [NaF] positron emission tomography [PET]/CT is an acceptable substitute)",
                            "type": "text"
                        },
                        {
                            "content": "must be offered participation in banking of specimens for future research; with the patient's consent, specimens (serum and bone marrow biopsy core) must be submitted to the repository; patient consent must be obtained before specimens are submitted",
                            "type": "text"
                        },
                        {
                            "content": "must have a diagnosis of neuroblastoma either by histologic verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines",
                            "type": "text"
                        },
                        {
                            "content": "must have evidence of acute leukemia in their peripheral blood or bone marrow; patients must have >= 5% blasts in the peripheral blood or bone marrow within 14 days prior to registration; at least >= 20% of those blasts must be CD22-positive (surface) based on local immunophenotyping and histopathology",
                            "type": "text"
                        },
                        {
                            "content": "must submit diagnostic bone marrow and peripheral blood specimens for immunophenotyping and selected molecular testing",
                            "type": "text"
                        },
                        {
                            "content": "must not have had previous allogeneic bone marrow transplant",
                            "type": "text"
                        },
                        {
                            "content": "with isolated myeloid sarcoma (myeloblastoma, chloroma, including leukemia cutis) but without evidence of APL by bone marrow or peripheral blood morphology are excluded",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ".",
                    "type": "text"
                }
            ]
        },
        "name": "Marrow"
    },
    {
        "English": {
            "content": [
                {
                    "content": "The subject must not:\nhave a tumor invading or encasing any major blood vessels,\nshow evidence of tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within ",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                },
                {
                    "content": " days \nbefore the first dose of cabozantinib, or\nshow radiographic evidence of cavitating pulmonary lesion(s).",
                    "id": "3",
                    "type": "text"
                }
            ],
            "id": "0"
        },
        "name": "Invading"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must have absolute neutrophil count >= ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "750",
                            "type": "text"
                        },
                        {
                            "content": "1000",
                            "type": "text"
                        },
                        {
                            "content": "1500",
                            "type": "text"
                        },
                        {
                            "content": "OTHER",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": " count per mm^3, Leukocytes >= ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "2000",
                            "type": "text"
                        },
                        {
                            "content": "2500",
                            "type": "text"
                        },
                        {
                            "content": "3000",
                            "type": "text"
                        },
                        {
                            "content": "OTHER",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": " count per mm^3, white blood cells >= ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "3000",
                            "type": "text"
                        },
                        {
                            "content": "3500",
                            "type": "text"
                        },
                        {
                            "content": "OTHER",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": " count per uL, and white blood cells < ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "30000",
                            "type": "text"
                        },
                        {
                            "content": "50000",
                            "type": "text"
                        },
                        {
                            "content": "OTHER",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": " count per uL.",
                    "type": "text"
                }
            ]
        },
        "name": "WBC"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must have:\n",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST), at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI,\nall imaging studies completed within 28 days prior to registration,\nat least five measurable cutaneous KS lesions or any number of lesions with systemic unresectable disease if they have Kaposi sarcoma (with no previous local radiation, surgical, or intralesional cytotoxic therapy that would prevent response assessment), and\nhistologically confirmed measurable or unmeasurable advanced or metastatic breast cancer for which standard curative measures do not exist or are no longer effective.",
                            "id": "3",
                            "type": "text"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Lesion Size"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must: ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "have grade 2 or higher peripheral neuropathy by Common Terminology Criteria for Adverse Events (CTCAE)",
                            "type": "text"
                        },
                        {
                            "content": "not have grade 2 or higher neuropathy",
                            "type": "text"
                        },
                        {
                            "content": "not have Pre-existing >= grade 2 sensory or motor peripheral neurotoxicity",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ".",
                    "type": "text"
                }
            ]
        },
        "name": "Neuropathy"
    },
    {
        "English": {
            "content": [
                {
                    "content": "For participants not on the Hodgkin lymphoma expansion cohort, subjects must have:\nLeukocytes count >= ",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "2,000",
                            "id": "3",
                            "type": "text"
                        },
                        {
                            "content": "1,000",
                            "id": "4",
                            "type": "text"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                },
                {
                    "content": " units/mm^3",
                    "id": "5",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "7",
                            "type": "text"
                        },
                        {
                            "content": "within 2 weeks prior to enrollment",
                            "id": "8",
                            "type": "text"
                        }
                    ],
                    "id": "6",
                    "name": "VARIABLE2",
                    "type": "dropdown"
                },
                {
                    "content": ",\nPlatelets >= ",
                    "id": "10",
                    "type": "text"
                },
                {
                    "content": [],
                    "id": "11",
                    "name": "VARIABLE5",
                    "type": "dropdown"
                },
                {
                    "content": " units/mm^3",
                    "id": "12",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "14",
                            "type": "text"
                        },
                        {
                            "content": "within 2 weeks prior to enrollment",
                            "id": "15",
                            "type": "text"
                        }
                    ],
                    "id": "13",
                    "name": "VARIABLE6",
                    "type": "dropdown"
                },
                {
                    "content": ",\nSerum lipase and amylase < ",
                    "id": "16",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "18",
                            "type": "text"
                        }
                    ],
                    "id": "17",
                    "name": "VARIABLE7",
                    "type": "dropdown"
                },
                {
                    "content": " x ULN",
                    "id": "19",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "21",
                            "type": "text"
                        },
                        {
                            "content": "within 2 weeks prior to enrollment",
                            "id": "22",
                            "type": "text"
                        }
                    ],
                    "id": "20",
                    "name": "VARIABLE8",
                    "type": "dropdown"
                },
                {
                    "content": ",\nCreatinine < ",
                    "id": "23",
                    "type": "text"
                },
                {
                    "content": [],
                    "id": "24",
                    "name": "VARIABLE9",
                    "type": "dropdown"
                },
                {
                    "content": " or creatinine clearance (CrCl) > ",
                    "id": "25",
                    "type": "text"
                },
                {
                    "content": [],
                    "id": "26",
                    "name": "VARIABLE10",
                    "type": "dropdown"
                },
                {
                    "content": " ml/min",
                    "id": "27",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "29",
                            "type": "text"
                        },
                        {
                            "content": "within 2 weeks prior to enrollment",
                            "id": "30",
                            "type": "text"
                        }
                    ],
                    "id": "28",
                    "name": "VARIABLE11",
                    "type": "dropdown"
                },
                {
                    "content": ",\nHemoglobin >= ",
                    "id": "31",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "33",
                            "type": "text"
                        }
                    ],
                    "id": "32",
                    "name": "VARIABLE12",
                    "type": "dropdown"
                },
                {
                    "content": " g/dL",
                    "id": "34",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "36",
                            "type": "text"
                        },
                        {
                            "content": "within 2 weeks prior to enrollment",
                            "id": "37",
                            "type": "text"
                        }
                    ],
                    "id": "35",
                    "name": "VARIABLE13",
                    "type": "dropdown"
                },
                {
                    "content": ",\nSerum albumin >= ",
                    "id": "38",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "40",
                            "type": "text"
                        }
                    ],
                    "id": "39",
                    "name": "VARIABLE14",
                    "type": "dropdown"
                },
                {
                    "content": " g/dL",
                    "id": "41",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "43",
                            "type": "text"
                        },
                        {
                            "content": "within 2 weeks prior to enrollment",
                            "id": "44",
                            "type": "text"
                        }
                    ],
                    "id": "42",
                    "name": "VARIABLE15",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Hodgkin"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must: ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "have the following tests within 28 days prior to registration to obtain baseline measurements:* Prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio (INR)/fibrinogen (all patients), Neurologic assessment",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": "have a partial thromboplastin time (PTT) <= ",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "1.2",
                                            "type": "text"
                                        },
                                        {
                                            "content": "1.25",
                                            "type": "text"
                                        },
                                        {
                                            "content": "1.3",
                                            "type": "text"
                                        },
                                        {
                                            "content": "1.5",
                                            "type": "text"
                                        },
                                        {
                                            "content": "2",
                                            "type": "text"
                                        },
                                        {
                                            "content": "OTHER",
                                            "type": "text"
                                        }
                                    ],
                                    "type": "dropdown"
                                },
                                {
                                    "content": "",
                                    "type": "text"
                                }
                            ],
                            "type": "progression"
                        },
                        {
                            "content": "Have an activated partial thromboplastin time (APTT) <= 1.5 x IULN",
                            "type": "text"
                        },
                        {
                            "content": "not be on warfarin if they cannot be switched to an acceptable alternative medication (i.e. low molecular weight heparin [LMWH]); prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving vorinostat concomitantly with coumarin-derivative anticoagulants",
                            "type": "text"
                        },
                        {
                            "content": "not have any serious or unstable pre-existing medical conditions (aside from malignancy exceptions specified above), including but not limited to, ongoing or active infection requiring parenteral antibiotics on day 1, history of bleeding diathesis or need for concurrent anticoagulation (international normalized ratio [INR] <= 1.5 and partial thromboplastin time [PTT] within 1.1 x ULN), or psychiatric illness/social situations that would limit compliance with study requirements, interfere with subject's safety, or obtaining informed consent; therapeutic level dosing of warfarin can be used with close monitoring of prothrombin time (PT)/INR by the site; exposure may be decreased due to enzyme induction when on treatment, thus warfarin dosing may need to be adjusted based upon PT/INR; consequently, when discontinuing dabrafenib, warfarin exposure may be increased and thus close monitoring via PT/INR and warfarin dose adjustments must be made as clinically appropriate; prophylactic low dose warfarin may be given to maintain central catheter patency",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ".",
                    "type": "text"
                }
            ]
        },
        "name": "Thromboplastin"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must:\n",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "not be receive any other investigational agents or drugs or anti-cancer agents,\nnot have been receiving corticosteroids and not have been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroids,\nnot have been receiving Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible, CYP3A4 agents: patients who are currently receiving drugs that are strong inducers or strong inhibitors of CYP3A4 are not eligible; strong inducers or inhibitors of CYP3A4 should be avoided from 14 days prior to enrollment to the end of the study, Note: CYP3A4 inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed,\nhave received their last dose of biologic agent >= 7 days prior to enrollment; in the event the patient has received another biologic agent and has experienced >= grade 2 myelosuppression, then at least three (3) weeks must have elapsed prior to enrollment; if the investigational or biologic agent has a prolonged half-life then at least three (3) weeks interval is required,\nnot have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or and not have recovered from adverse events (other than alopecia) due to agents administered more than 4 weeks earlier; however, the following therapies are allowed: Hormone-replacement therapy or oral contraceptives, Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1), or Palliative radiotherapy for bone metastases > 2 weeks prior to cycle 1, day 1.",
                            "id": "3",
                            "type": "text"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Investigational Agents"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients: ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "must have the following histologic epithelial cell types to eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, squamous cell carcinoma (including variants such as verrucous carcinoma, spindle cell carcinoma, carcinoma not otherwise specified [NOS], etc.), transitional cell carcinoma, malignant Brenners tumor, sinonasal carcinoma, nasopharyngeal carcinoma, primary cervical cancer I-IIA with squamous cell carcinoma, adenocarcinoma initially treated with a standard radical hysterectomy with pelvic lymphadenectomy, anal intraepithelial neoplasia, or cutaneous Kaposis sarcoma (KS), urothelial carcinoma of the bladder, rectal cancer histology other than adenocarcinoma, T cell and NK cell lymphomas, Merkel cell carcinoma, other non-melanoma skin cancers, sweat gland tumors, invasive lobular carcinoma",
                            "type": "text"
                        },
                        {
                            "content": "may have adequately managed stage I or II cancer from which the patient is currently in complete remission (except follicular thyroid or prostate cancer where patient is not required to be in complete remission)",
                            "type": "text"
                        },
                        {
                            "content": "may have co-existing endometrial cancer so long as the primary origin of invasive tumor is  ovarian or peritoneal, locally advanced, previously untreated squamous cell carcinoma of the vulva,\nmust not have hypopharynx primaries, poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid and small cell carcinoma",
                            "type": "text"
                        },
                        {
                            "content": "may have a history of acute myeloid leukemia (AML)",
                            "type": "text"
                        },
                        {
                            "content": "who are men receiving active surveillance for prostate cancer may also be enrolled",
                            "type": "text"
                        },
                        {
                            "content": "with prior early stage breast cancers are also allowed as long as prior treatment did not include aromatase inhibitors",
                            "type": "text"
                        },
                        {
                            "content": "must have histologically or cytological confirmed malignancy in the following disease groups: melanoma that is metastatic or unresectable, non-small cell lung carcinoma, renal cell carcinoma, sarcoma, colon carcinoma, or non-Hodgkin lymphoma for which standard curative or palliative measures do not exist or are no longer effective",
                            "type": "text"
                        },
                        {
                            "content": "with non-small lung cancer must have had prior epidermal growth factor receptor (EGFR) and anaplastic lymphoma receptor tyrosine kinase (ALK) testing",
                            "type": "text"
                        },
                        {
                            "content": "with sensitizing mutations in EGFR or ALK rearrangements should have been treated with prior targeted agents and have had progression or discontinued due to toxicity from these agents",
                            "type": "text"
                        },
                        {
                            "content": "may have colloid, islet cell, serous or mucinous cystadenoma or cystadenocarcinoma, carcinoid, small or large cell carcinoma, intraductal oncocytic papillary neoplasms (IOPN), osteoclast-like giant cell tumors, acinar cell carcinoma, pancreatoblastoma, solid pseudopapillary tumors, or non-epithelial tumors (sarcomas, gastrointestinal [GI] stromal tumor, lymphoma)",
                            "type": "text"
                        },
                        {
                            "content": "who were initially diagnosed with low-grade serous ovarian or peritoneal carcinoma that recur as low-grade serous carcinoma (invasive micropapillary serous carcinoma or invasive grade I serous carcinomas as defined by GOG, Federation of Obstetricians and Gynecologists [FIGO], World Health Organization [WHO] or Silverberg)",
                            "type": "text"
                        },
                        {
                            "content": "must be <= 18 years of age for medullary thyroid carcinoma (MTC), renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC)",
                            "type": "text"
                        },
                        {
                            "content": "must not not have colonic polyps, non-melanoma skin cancer, ductal carcinoma in situ, bladder carcinoma in situ, or carcinoma-in-situ of the cervix",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": "must not have other invasive malignancy <= ",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "1",
                                            "type": "text"
                                        },
                                        {
                                            "content": "2",
                                            "type": "text"
                                        },
                                        {
                                            "content": "3",
                                            "type": "text"
                                        },
                                        {
                                            "content": "5",
                                            "type": "text"
                                        },
                                        {
                                            "content": "OTHER",
                                            "type": "text"
                                        }
                                    ],
                                    "type": "dropdown"
                                },
                                {
                                    "content": " years prior to registration",
                                    "type": "text"
                                }
                            ],
                            "type": "progression"
                        },
                        {
                            "content": "all therapy at least 2 years before enrollment with no evidence of disease since therapy completion if they had prior malignancies",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ".",
                    "type": "text"
                }
            ]
        },
        "name": "Squamous"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must not have: ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "known central nervous system (CNS) metastases or seizure disorder, (patients with known brain metastases that have been successfully treated and stable for >= 6 months without requirement for corticosteroids and without seizure activity will be eligible)",
                            "type": "text"
                        },
                        {
                            "content": "active seizure or history of seizure disorder",
                            "type": "text"
                        },
                        {
                            "content": "a history of intractable epilepsy, or uncontrolled seizure disorder",
                            "type": "text"
                        },
                        {
                            "content": "a history of encephalitis, multiple sclerosis, or seizures within the last year (from seizure disorder or brain metastasis)",
                            "type": "text"
                        },
                        {
                            "content": "comorbid conditions: patients are unable to participate due to the following:* Generalized or partial seizure disorder that is uncontrolled at the time of registration; the definition of controlled generalized seizures is patients must be on a stable dose of anti-seizure medication and without generalized seizures for at least 10 days prior to registration; the definition of controlled partial seizures is patients must be on a stable dose of anti-seizure medication for at least 10 days prior to registration; patients with occasional breakthrough partial seizures are allowed at treating physician's discretion* Grade 3 or 4 thromboembolic disease within 6 months (mo) of registration* Known history of prolonged QT syndrome",
                            "type": "text"
                        },
                        {
                            "content": "a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection; examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, extensive bilateral lung disease on high resolution computed tomography scan or any psychiatric disorder that prohibits obtaining informed consent",
                            "type": "text"
                        },
                        {
                            "content": "",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ".",
                    "type": "text"
                }
            ]
        },
        "name": "Seizure"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <= ",
                    "id": "1",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "2.5",
                            "id": "3",
                            "type": "text"
                        },
                        {
                            "content": "3",
                            "id": "4",
                            "type": "text"
                        },
                        {
                            "content": "5",
                            "id": "5",
                            "type": "text"
                        },
                        {
                            "content": "10",
                            "id": "6",
                            "type": "text"
                        },
                        {
                            "content": "OTHER",
                            "id": "7",
                            "type": "text"
                        }
                    ],
                    "id": "2",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                },
                {
                    "content": " x IULN",
                    "id": "8",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "id": "10",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": " within",
                                    "id": "12",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "7",
                                            "id": "14",
                                            "type": "text"
                                        },
                                        {
                                            "content": "14",
                                            "id": "15",
                                            "type": "text"
                                        },
                                        {
                                            "content": "OTHER",
                                            "id": "16",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "13",
                                    "name": "VARIABLE3",
                                    "type": "dropdown"
                                },
                                {
                                    "content": " days of registration",
                                    "id": "17",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "",
                                            "id": "19",
                                            "type": "text"
                                        },
                                        {
                                            "content": " if AST and/or ALT is >= ULN but <= 3 x ULN, serologic testing for hepatitis B and C must be performed and results for viral infection must be negative.",
                                            "id": "20",
                                            "type": "text"
                                        }
                                    ],
                                    "id": "18",
                                    "name": "VARIABLE4",
                                    "type": "dropdown"
                                }
                            ],
                            "id": "11",
                            "type": "progression"
                        }
                    ],
                    "id": "9",
                    "name": "VARIABLE2",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "AST"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biological composition to ",
                    "id": "5",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "ABT-888",
                            "id": "7",
                            "type": "text"
                        },
                        {
                            "content": "carboplatin",
                            "id": "8",
                            "type": "text"
                        },
                        {
                            "content": "cisplatin",
                            "id": "9",
                            "type": "text"
                        },
                        {
                            "content": "dabrafenib",
                            "id": "10",
                            "type": "text"
                        },
                        {
                            "content": "dimethyl sulfoxide (DMSO)",
                            "id": "11",
                            "type": "text"
                        },
                        {
                            "content": "5-fluorouracil",
                            "id": "12",
                            "type": "text"
                        },
                        {
                            "content": "hydroxyurea",
                            "id": "13",
                            "type": "text"
                        },
                        {
                            "content": "pomalidomide (e.g. lenalidomide, thalidomide)",
                            "id": "14",
                            "type": "text"
                        },
                        {
                            "content": "Cremephor",
                            "id": "15",
                            "type": "text"
                        },
                        {
                            "content": "ibrutinib",
                            "id": "16",
                            "type": "text"
                        },
                        {
                            "content": "paclitaxel",
                            "id": "17",
                            "type": "text"
                        },
                        {
                            "content": "veliparib",
                            "id": "18",
                            "type": "text"
                        },
                        {
                            "content": "cabozantinib",
                            "id": "19",
                            "type": "text"
                        },
                        {
                            "content": "nivolumab",
                            "id": "20",
                            "type": "text"
                        },
                        {
                            "content": "ipilimumab",
                            "id": "21",
                            "type": "text"
                        },
                        {
                            "content": "sEphB4-HSA",
                            "id": "22",
                            "type": "text"
                        },
                        {
                            "content": "talazoparib (BMN 673)",
                            "id": "23",
                            "type": "text"
                        },
                        {
                            "content": "blinatomumab",
                            "id": "24",
                            "type": "text"
                        },
                        {
                            "content": "dasatinib or ganitumab selumetinib inotuzumab ozogamicin",
                            "id": "25",
                            "type": "text"
                        },
                        {
                            "content": "vorinostat",
                            "id": "26",
                            "type": "text"
                        },
                        {
                            "content": "romidepsin, including cyclic tetrapeptide compounds",
                            "id": "27",
                            "type": "text"
                        },
                        {
                            "content": "MLN8237",
                            "id": "28",
                            "type": "text"
                        },
                        {
                            "content": "bortezomib or rituximab",
                            "id": "29",
                            "type": "text"
                        },
                        {
                            "content": "AZD1775 (MK-1775) TRC102 or TMZ",
                            "id": "30",
                            "type": "text"
                        },
                        {
                            "content": "XL184",
                            "id": "31",
                            "type": "text"
                        },
                        {
                            "content": "CYT107",
                            "id": "32",
                            "type": "text"
                        },
                        {
                            "content": "belinostat, including hydroxamate compounds or arginine",
                            "id": "33",
                            "type": "text"
                        },
                        {
                            "content": "navitoclax",
                            "id": "34",
                            "type": "text"
                        },
                        {
                            "content": "dabrafenib, or trametinib, or excipients or to dimethyl sulfoxide (DMSO)",
                            "id": "35",
                            "type": "text"
                        },
                        {
                            "content": "AZD 1775 (MK-1775)",
                            "id": "36",
                            "type": "text"
                        },
                        {
                            "content": "gemcitabine",
                            "id": "37",
                            "type": "text"
                        },
                        {
                            "content": "clofarabine or bortezomib gemcitabine (gemcitabine hydrochloride) or cisplatin",
                            "id": "38",
                            "type": "text"
                        },
                        {
                            "content": "MLN0128 (TAK-228) navitoclax or sorafenib",
                            "id": "39",
                            "type": "text"
                        },
                        {
                            "content": "MLN0128 (TAK-228) or ziv-aflibercept",
                            "id": "40",
                            "type": "text"
                        },
                        {
                            "content": "MLN0128",
                            "id": "41",
                            "type": "text"
                        },
                        {
                            "content": "bevacizumab",
                            "id": "42",
                            "type": "text"
                        },
                        {
                            "content": "cabozantinib",
                            "id": "43",
                            "type": "text"
                        },
                        {
                            "content": "MK-3475 and ziv-aflibercept",
                            "id": "44",
                            "type": "text"
                        },
                        {
                            "content": "nivolumab",
                            "id": "45",
                            "type": "text"
                        },
                        {
                            "content": "afatinib and/or cetuximab",
                            "id": "46",
                            "type": "text"
                        },
                        {
                            "content": "GDC-0449",
                            "id": "47",
                            "type": "text"
                        },
                        {
                            "content": "MLN0128 (TAK-228)",
                            "id": "48",
                            "type": "text"
                        },
                        {
                            "content": "TRC102 or pemetrexed and cisplatin",
                            "id": "49",
                            "type": "text"
                        },
                        {
                            "content": "AZD1775 or belinostat",
                            "id": "50",
                            "type": "text"
                        },
                        {
                            "content": "IPdR",
                            "id": "51",
                            "type": "text"
                        },
                        {
                            "content": "18F-fluorothymidine",
                            "id": "52",
                            "type": "text"
                        },
                        {
                            "content": "18F-FES",
                            "id": "53",
                            "type": "text"
                        },
                        {
                            "content": "MLN0128 (TAK-228)",
                            "id": "54",
                            "type": "text"
                        },
                        {
                            "content": "cisplatin",
                            "id": "55",
                            "type": "text"
                        },
                        {
                            "content": "carboplatin",
                            "id": "56",
                            "type": "text"
                        },
                        {
                            "content": "etoposide",
                            "id": "57",
                            "type": "text"
                        },
                        {
                            "content": "temozolomide or capecitabine",
                            "id": "58",
                            "type": "text"
                        },
                        {
                            "content": "entinostat",
                            "id": "59",
                            "type": "text"
                        },
                        {
                            "content": "nivolumab, or ipilimumab",
                            "id": "60",
                            "type": "text"
                        },
                        {
                            "content": "triapine",
                            "id": "61",
                            "type": "text"
                        },
                        {
                            "content": "AT13387 or paclitaxel",
                            "id": "62",
                            "type": "text"
                        },
                        {
                            "content": "MLN0128 (TAK-228)",
                            "id": "63",
                            "type": "text"
                        },
                        {
                            "content": "onalespib or AT7519M",
                            "id": "64",
                            "type": "text"
                        },
                        {
                            "content": "MLN0128 (TAK-228) or osimertinib (AZD9291)",
                            "id": "65",
                            "type": "text"
                        },
                        {
                            "content": "MEDI-570 methoxyamine or to pemetrexed, erlotinib",
                            "id": "66",
                            "type": "text"
                        },
                        {
                            "content": "onalespib",
                            "id": "67",
                            "type": "text"
                        },
                        {
                            "content": "M6620 (VX-970)",
                            "id": "68",
                            "type": "text"
                        },
                        {
                            "content": "AT13387 (onalespib)",
                            "id": "69",
                            "type": "text"
                        },
                        {
                            "content": "MK-3475 (pembrolizumab)",
                            "id": "70",
                            "type": "text"
                        },
                        {
                            "content": "triapine",
                            "id": "71",
                            "type": "text"
                        },
                        {
                            "content": "M6620",
                            "id": "72",
                            "type": "text"
                        },
                        {
                            "content": "gemcitabine",
                            "id": "73",
                            "type": "text"
                        },
                        {
                            "content": "VX-970 or irinotecan",
                            "id": "74",
                            "type": "text"
                        },
                        {
                            "content": "VX-970",
                            "id": "75",
                            "type": "text"
                        },
                        {
                            "content": "gemcitabine",
                            "id": "76",
                            "type": "text"
                        },
                        {
                            "content": "veliparib",
                            "id": "77",
                            "type": "text"
                        },
                        {
                            "content": "MM-398",
                            "id": "78",
                            "type": "text"
                        },
                        {
                            "content": "nelfinavir",
                            "id": "79",
                            "type": "text"
                        },
                        {
                            "content": "selumetinib",
                            "id": "80",
                            "type": "text"
                        },
                        {
                            "content": "nivolumab",
                            "id": "81",
                            "type": "text"
                        },
                        {
                            "content": "ipilimumab",
                            "id": "82",
                            "type": "text"
                        },
                        {
                            "content": "blinatomumab",
                            "id": "83",
                            "type": "text"
                        },
                        {
                            "content": "MEDI4736 or other PD-1 or PD-L1",
                            "id": "84",
                            "type": "text"
                        },
                        {
                            "content": "macrolide and ketolide antibiotics",
                            "id": "85",
                            "type": "text"
                        },
                        {
                            "content": "temsirolimus/other mTOR temozolomide",
                            "id": "86",
                            "type": "text"
                        },
                        {
                            "content": "irinotecan",
                            "id": "87",
                            "type": "text"
                        },
                        {
                            "content": "MK-3475 (pembrolizumab)",
                            "id": "88",
                            "type": "text"
                        },
                        {
                            "content": "anti-PD1 or PD-L1",
                            "id": "89",
                            "type": "text"
                        },
                        {
                            "content": "entinostat",
                            "id": "90",
                            "type": "text"
                        },
                        {
                            "content": "AZD9291 (osimertinib) or bevacizumab",
                            "id": "91",
                            "type": "text"
                        },
                        {
                            "content": "BAL101553",
                            "id": "92",
                            "type": "text"
                        },
                        {
                            "content": "IPdR",
                            "id": "93",
                            "type": "text"
                        },
                        {
                            "content": "PT2385",
                            "id": "94",
                            "type": "text"
                        },
                        {
                            "content": "atezolizumab",
                            "id": "95",
                            "type": "text"
                        },
                        {
                            "content": "olaparib",
                            "id": "96",
                            "type": "text"
                        },
                        {
                            "content": "cediranib",
                            "id": "97",
                            "type": "text"
                        },
                        {
                            "content": "carboplatin",
                            "id": "98",
                            "type": "text"
                        },
                        {
                            "content": "or etoposide",
                            "id": "99",
                            "type": "text"
                        },
                        {
                            "content": "olaparib and AT13387",
                            "id": "100",
                            "type": "text"
                        },
                        {
                            "content": "bevacizumab",
                            "id": "101",
                            "type": "text"
                        }
                    ],
                    "id": "6",
                    "name": "VARIABLE1",
                    "type": "dropdown"
                }
            ],
            "id": "0"
        },
        "name": "Allergic"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must have: Platelets >= ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "100,000",
                            "type": "text"
                        },
                        {
                            "content": "75,000",
                            "type": "text"
                        },
                        {
                            "content": "OTHER",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": "/mcL",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": " obtained <= ",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "14",
                                            "type": "text"
                                        },
                                        {
                                            "content": "21",
                                            "type": "text"
                                        },
                                        {
                                            "content": "30",
                                            "type": "text"
                                        },
                                        {
                                            "content": "OTHER",
                                            "type": "text"
                                        }
                                    ],
                                    "type": "dropdown"
                                },
                                {
                                    "content": " days prior to registration",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "",
                                            "type": "text"
                                        },
                                        {
                                            "content": " (transfusion independent, defined as not receiving platelet transfusions for at least \n7 days prior to enrollment)",
                                            "type": "text"
                                        }
                                    ],
                                    "type": "dropdown"
                                }
                            ],
                            "type": "progression"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ".",
                    "type": "text"
                }
            ]
        },
        "name": "Platelets"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients who: ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": [
                                {
                                    "content": "are pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "",
                                            "type": "text"
                                        }
                                    ],
                                    "type": "dropdown"
                                }
                            ],
                            "type": "progression"
                        },
                        {
                            "content": "are breastfeeding should discontinue breastfeeding prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drug",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": "are of childbearing potential must have a negative serum pregnancy test within ",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "7",
                                            "type": "text"
                                        },
                                        {
                                            "content": "14",
                                            "type": "text"
                                        },
                                        {
                                            "content": "21",
                                            "type": "text"
                                        },
                                        {
                                            "content": "",
                                            "type": "text"
                                        }
                                    ],
                                    "type": "dropdown"
                                },
                                {
                                    "content": " days before start of the trial",
                                    "type": "text"
                                }
                            ],
                            "type": "progression"
                        },
                        {
                            "content": "have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are not postmenopausal are eligible; postmenopausal is defined as amenorrhea >= 12 consecutive months unless amenorrhea is possibly due to prior chemotherapy, antiestrogens, ovarian suppression or any other reversible reason",
                            "type": "text"
                        },
                        {
                            "content": "are sexually active must agree to use both a barrier method and a second method of birth control during the course of the study and for 23 or 31 weeks for women and men respectively after the last dose of study drugs",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ".",
                    "type": "text"
                }
            ]
        },
        "name": "Pregnant"
    },
    {
        "English": {
            "content": [
                {
                    "content": "Patients must: ",
                    "type": "text"
                },
                {
                    "content": [
                        {
                            "content": "not have a systemic bacterial, fungal, or viral infection that is not controlled, (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement despite appropriate antibiotics or other treatment)",
                            "type": "text"
                        },
                        {
                            "content": [
                                {
                                    "content": "not have signs or symptoms of infection within ",
                                    "type": "text"
                                },
                                {
                                    "content": [
                                        {
                                            "content": "2",
                                            "type": "text"
                                        },
                                        {
                                            "content": "OTHER",
                                            "type": "text"
                                        }
                                    ],
                                    "type": "dropdown"
                                },
                                {
                                    "content": " weeks prior to cycle 1, day 1",
                                    "type": "text"
                                }
                            ],
                            "type": "progression"
                        },
                        {
                            "content": "not have clinical signs or symptoms of active tuberculosis infection",
                            "type": "text"
                        }
                    ],
                    "type": "dropdown"
                },
                {
                    "content": ".",
                    "type": "text"
                }
            ]
        },
        "name": "Signs"
    }
]